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SUMMARY 
 
While one-year graft survival rates for deceased donor transplants have soared from 
about 40% in 1975 to more than 90% in 2005 [1], the long-term perspective has changed 
very little. From 1996-2005, 10-year deceased donor graft survival has remained at about 
40%, only slightly above that of the 1987-1995 period [1]. Furthermore, the gain in graft 
survival between 1988 and 1995, based on calculated real half-lives, has been reported as 
4.7 or 8.4 months, for first or further deceased donor transplants, respectively. These 
numbers reveal that estimates of doubled half-lives from 1988 to 1995, which were based 
on projected half-lives, were far from accurate [2]. The remarkable short-term 
improvements have thus not translated into long-term advantages [1, 2]. 
 
Improving long-term post-transplantation outcomes should therefore be a priority of 
transplant recipient management. Investing in chronic illness management, which focuses 
on improving patient self-management and medication adherence, is a promising pathway 
in that direction. 
 
Chronic illness management has lately emerged as a response to the reported dramatic 
global increase in chronic conditions [3]. A chronic condition is defined as one that is 
never completely cured [4] and that requires ongoing long-term management of the 
illness, coexisting morbidities, treatments, or measures to prevent further disability [3]. 
Such management imposes a heavy burden on current health care systems. The gravity of 
the situation is increased by the application of acute care models (i.e., prioritizing the 
treatment and cure of peoples’ acute and urgent symptoms), which have limited effects 
on chronic conditions [3]. Effective chronic care models, i.e., care that improves 
chronically ill patient populations’ conditions, are characterized by continuity of care, 
partnership with patients, families, and communities, support for patients in improving 
self-management skills, attention to preventive measures, decision-making support for 
healthcare providers, and availability of clinical information systems [3, 5-7]. Empirical 
evidence underlines the effectiveness of chronic illness management [8-10]. Of these, 
Summary 
7 
models that incorporate patient self-management support show the most improved 
outcomes [3, 7, 11].  
 
Patient self-management refers to actions performed by patients for themselves in daily 
life to manage their illness and treatment, and to avoid health deterioration [5, 12]. 
Related support consists of two components: the training of disease specific knowledge 
and technical skills, and the training of non-disease specific problem solving and other 
skills to assist behavior change [13]. A growing body of evidence in patients with chronic 
illness demonstrates that supporting patient self-management positively impacts 
outcomes [10, 14-19]. 
 
An essential component of patient self-management is managing the medical regimen, 
including adherence, i.e., “the extent to which a person’s behavior (taking medications, 
following a recommended diet, and/or executing lifestyle changes) corresponds with the 
agreed recommendations of a healthcare provider” [8]. The scale and impact of 
medication adherence regarding patient outcomes have been widely demonstrated in 
chronic patient populations [20-22]. Recent literature reviews regarding kidney 
transplantation [23-25] demonstrate that non-adherence to immunosuppressive therapy is 
a major contributor to poor clinical outcomes. Given that inadequate medication 
adherence has critical implications on health outcomes, focusing prominently on 
adherence as an essential part of patient self-management is crucial to improve outcomes 
in the kidney transplant population. 
 
The gaps in the literature guiding this research program were as follow: 1) as no 
conceptualization was available for patient self-management in the kidney transplant 
population, it was necessary to define one; 2) little information was available on the 
diagnostic accuracy of measurement methods to identify medication non-adherence in the 
kidney transplant population, 3) there was a need to test medication adherence enhancing 
interventions, as very little information was available on this patient group; and 4) there 
was a need to evaluate a technological intervention designed for patient use, as such 
information was lacking. 
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The work and studies incorporated in this research program to address these gaps used a 
variety of methods, including both quantitative and qualitative approaches. The studies 
are summarized as follows. 
 
First, a comprehensive definition of kidney transplant recipient self-management has 
been developed, summarizing evidence from the transplant literature. This definition 
provides both detailed kidney transplant specific self-management activities and core 
skills that patients may acquire or further develop for successful self-management. It also 
provides a conceptual model using a care paradigm that regards the patient as a worker 
having expertise at managing the illness in daily life. This is a crucial aspect of chronic 
illness management. The model outlined here can be used as a basis for the development 
of systematic and comprehensive kidney transplant recipient self-management support. It 
furthermore constitutes a crucial first step to allow transplant clinics to shift from an 
acute to a chronic care model for long-term transplant recipient management.  
 
Second, the literature summarized current understanding about medication non-
adherence, and provided an overview of current knowledge regarding correlates of 
medication non-adherence, as well as of medication adherence enhancing interventions in 
the kidney transplant population. Further, to offer a concrete example on how to 
implement theory based adherence enhancing strategies into an individual situation, it 
reports on a case study [26]. 
 
Third, we used a cross sectional study to test the diagnostic accuracy of 
immunosuppression assay, patients’ self-reports, clinicians’ collateral reports, and 
constructed composite adherence scores using electronic monitoring as a reference 
standard for a convenience sample of 249 kidney transplant recipients (female: 43.4%; 
mean age 53.6 (SD: 12.7), median 7 years (IQR: 9 years) post-transplantation). 
Medication non-adherence prevalence, as assessed by electronic monitoring, was 17.3%. 
Across the measurement methods, prevalence rates varied from 12.4% for self-reports to 
38.9% for composite adherence scores. Of all the measures, the composite adherence 
score yielded both the highest sensitivity (72.1%) and the highest likelihood ratio of a 
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positive test (2.74), while collateral reports of at least three clinicians showed the highest 
specificity (93.1%). While no measures showed high sensitivity alongside high 
specificity, combining measures increased diagnostic accuracy, indicating the relevance 
of combined measures for clinical and research purposes [27]. 
 
Fourth, we tested the efficacy of an educational/behavioral intervention and enhanced 
social support intervention to increase medication adherence in 18 non-adherent renal 
transplant recipients (age: 45.6±1.2 yr; 78.6% male). Using a pilot randomized controlled 
trial, the study showed a remarkable decrease in non-adherence in the intervention group 
(IG, n=6) and in the enhanced standard care group (EUCG, n=12) over the first three 
months (IG, χ2 =3.97, df=1, p=.04; EUCG, χ2=3.40, df=1, p=.06). The interventions 
appeared to add further benefit to medication adherence levels in the IG, as the greatest 
decrease in non-adherence was observed there. This result was not, however, statistically 
significant (at 90 days:, χ2=1.05, df=1, p=.31), owing to insufficient sample size [28]. 
 
Fifth, we tested the content validity and usability of a computer based patient information 
and education tool (OTISTM), from the perspectives of clinicians and patients. Using 
qualitative methods and a purposive sample of 8 clinicians and 14 patients, the study 
identified deviations from current medical practice regarding the content, language, and 
information structure of OTISTM. Seven of the eight clinicians rated OTISTM as non-
relevant for implementation in clinical practice and all patients encountered usability 
problems, mostly regarding the program’s interface. Emerging categories from the 
patients’ perspectives vis à vis content were knowledge acquisition, illness management, 
and partnership forming. The study demonstrated the need to establish the presented 
material’s content validity and usability by involving clinicians and patients well before 
its clinical implementation phase [29].  
 
The results of our research program contribute in five main ways to the evidence base 
regarding kidney transplant recipients’ self-management, and, more specifically, 
adherence to post-transplantation medication taking. First, it described, for the first time, 
a comprehensive kidney transplant recipient self-management model, outlining disease 
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specific activities and non-disease specific patient core skills. Second, it summarized 
knowledge on current understanding, correlates of medication adherence, and post-
transplant adherence enhancing interventions. Third, it added detailed knowledge on 
diagnostic accuracy of state-of-the art measures to identify medication non-adherence in 
renal transplant recipients. Fourth, it provided evidence and thus added to the very limited 
amount of available information, supporting the feasibility of enhancing medication 
adherence in non-adherent renal transplant recipients using a package of educational-
behavioral interventions and social support. Finally, it suggested that in order to ensure 
and maximize benefits to its intended users, technological interventions for patient use 
need to be evaluated with regard to usability and content validity. 
 
Future research should focus on further development and testing of the conceptual model 
presented here, with attention to relationships between the model variables, to develop 
and evaluate valid kidney transplant recipient self-management measures, and to test 
whether supporting such self-management results in improved long-term health 
outcomes. 
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INTRODUCTION 
Despite impressive scientific advances in immunosuppression and in other aspects in the 
transplant management, which have reduced the incidence of acute and chronic rejection, 
recent evidence shows that no significant improvement in long-term kidney 
transplantation outcomes has been achieved since the 1970’s [1]. One-year post-graft 
survival rates for deceased donor transplants have improved impressively, from about 
40% in 1975 to more than 90% in 2005. Yet, while this level of success can scarcely be 
improved [1], such remarkable progress has not translated into long-term advantages [2]. 
Improving long-term outcomes should therefore be afforded a top priority in transplant-
related research. Refining chronic illness management, including patient self-
management and medication adherence, offers excellent potential for progress. 
This thesis contributes to this goal by taking preliminary steps towards developing a 
kidney transplant recipients’ self-management program. It consists of 7 Chapters, of 
which three detail original studies. Chapters 3-5 have been published, and Chapter 6 has 
been accepted for publication, all in peer reviewed journals. 
In the context of kidney transplantation, the idea of chronic illness management as a care 
model is new and relatively unexplored: to date, no comprehensively study exists on 
kidney transplant recipients’ self-management. Therefore, Chapters 1 and 2 below 
provide the background and aims of this thesis, based on the literature on chronic illness 
and kidney transplant groups. 
? Chapter 1 provides a literature based introduction to the use of chronic illness 
management to improve kidney transplant outcomes. This includes an 
introduction to patient self-management and medication adherence. More 
specifically, the description of the kidney transplant recipient self-management 
model outlines sets of activities and core skills to achieve behavior change. 
? Chapter 2 describes the aims of the research program. 
 
Furthermore, as transplant recipients’ medication management /adherence occupies a 
central role, both within self-management and within the expertise of the research group 
which embedded this thesis, further studies were directed to examine medication regimen 
adherence (Chapters 3-5):  
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? Chapter 3 summarizes correlates of medication adherence and adherence 
enhancing interventions, and provides a case study to illustrate the practicability 
of translating theory-driven interventions into specific situations; 
? Chapter 4 explores the measurement of medication adherence; and 
? Chapter 5 reports on an intervention study testing theory based adherence 
enhancing interventions in non-adherent kidney transplant recipients. 
 
Additionally, given the increasing importance of information technology in healthcare, 
this research program also included steps towards employing computer-assisted learning 
in kidney transplant clinics. 
? Chapter 6 reports on a study evaluating a computer-based patient information 
and education tool designed to enhance patient self-management after kidney 
transplantation.  
 
To conclude, 
? Chapter 7 discusses the research program as a whole by placing the findings in a 
broader research and clinical practice context, identifying methodological issues, 
and suggesting further steps to develop and strengthen kidney transplant self-
management programs. 
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Chapter 1 
Chronic illness management as an instrument to improve long-term 
kidney transplant outcomes 
 
1.0. Long-term kidney transplant outcomes 
Long-term graft survival after kidney transplantation has remained practically unchanged 
for three decades, despite significant improvements in short-term graft survival and 
immunosuppression [1]. Based on data from the UCLA Kidney Transplant Registry 
(n=46.000, start 1969), the United Network of Organ Sharing (UNOS) Kidney Transplant 
Registry (n=80.000, start 1987) and 138,000 transplant cases from 1996-2005, Kaneku et 
al. reported on a thirty-year trend in kidney transplants. While first-year graft survival for 
deceased donor grafts improved impressively from about 40% in 1975 to more than 90% 
in 2005, the long-term perspective is strikingly different. From 1987-1995, ten year 
deceased donor graft survival improved slowly from about 35% to about 40%, with no 
further advancement since then [1]. Furthermore, based on the US Scientific Renal 
Transplant Registry database for transplants performed between 1988 and 1995, the 
increase in graft survival over this period, based on real half-lives, was 4.7 months in 
deceased donor transplants, and 8.4 months in first deceased donor transplants. Further, 
whereas projected half-lives of deceased donor transplants (including re-transplant 
recipients) increased from 7.9 years in 1988 to 13.8 in 1995, a Kaplan Meier analysis 
yielded significantly shorter actual half-lives, i.e., 6.0 years in 1988 and 8.0 in 1995 [2]. 
These numbers reveal that the expected doubling of half-lives from 1988 to 1995, based 
on projected half-lives, resulted from an overestimation. These findings indicate that the 
remarkable short-term improvements have not translated into a long-term advantage [2]. 
The leading cause of late graft failure is chronic allograft nephropathy, i.e., a progressive 
decline in renal function, with prevalence rates of 81-86% [1, 3]. Evidence suggests that 
this condition is multifactorial in origin, with both immunological (e.g., human leukocyte 
antigen mismatch, inadequate immunosuppression, previous episodes of acute rejection) 
and non-immunological risk factors (e.g., age, race, sex, hypertension, hyperlipidemia, 
cytomegalovirus infection, recurrent and de novo disease) contributing to the decline of 
Chapter 1: Chronic illness management as an instrument to improve long-term kidney 
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renal function [3, 4]. Additionally, patient death is the most significant adverse outcome 
after kidney transplantation. According to the UNOS, the known long-term leading 
causes of death in deceased donor kidney transplant recipients from 1993-2004 were 
cardiovascular disease (22%), infection (16%), malignancy (6.8%), 
cerebrovascular/hemorrhage (6.3%), trauma (0.6%), non-adherence (0.2%), graft failure 
(1%), and various other (19%) [4].  
 
The suggested insignificant contribution of non-adherence to patient outcomes may be 
due to a lack of routine or standardized non-adherence assessment in research and clinical 
care, as it contrasts directly with evidence demonstrating the detrimental impact of non-
adherence on clinical outcomes [5-7]. However, other sources (e.g., [8]) have also 
neglected the patient’s role in managing kidney transplantation as a possible pathway to 
maintaining graft function, overall health and thus long-term patient and graft survival. 
Only Gordon et al. (2005) have recently suggested considering the patient’s role in 
managing aspects of transplantation in daily life when developing long-term strategies. 
More specifically, they suggested that patient engagement and self-management activities 
may be vital in limiting the decline of graft function, thus shifting from a pure molecular 
perspective to a behavioral level [9]. 
 
As patient self-management is an essential characteristic of chronic illness management, 
the following paragraphs discuss first chronic illness management, thus providing a 
context for patient self-management, then elaborate the definition of patient self-
management as it relates to kidney transplantation. 
 
1.1. Chronic illness management 
With the 2002 global report, “Innovative care for chronic conditions: building blocks for 
action,” the World Health Organization alerted policy makers and health care workers of 
the dramatic global increase of chronic conditions, and of the challenges this increase 
would entail for current and future health care systems [10]. Current health care systems 
use an acute care model, which prioritizes the treatment and cure of acute and urgent 
symptoms. However, such a model is ineffective when dealing with chronic conditions, 
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i.e., conditions that are not completely curable [11] and that require ongoing management 
across years due to the illness, coexisting morbidities, treatment, or prevention of further 
disability [10]. Chronic conditions have lifelong influence on people’s daily lives. It is 
estimated that up to 99% [12] of daily chronic illness management is left to patients and 
their families, who are undersupplied by acute care models, which focus on identifying 
and treating the urgent acute episodic health problems of the remaining 1% [10, 12, 13]. 
 
In contrast, effective chronic care models focus on maintaining or improving the health of 
chronically ill populations. They are characterized by a number of building blocks that 
refer to continuity of care, partnership with patients, families, and communities, support 
for patients in improving their self-management skills, attention to preventive measures, 
decision-making support for healthcare providers, and availability of clinical information 
systems [10, 13-15].  
Empirical evidence underlines the effectiveness of chronic illness management. Improved 
outcomes are observed among chronically ill patients when the care system shifts from an 
acute/curative model to one of chronic management [15-18]. Models incorporating 
elements of patient self-management support show outcomes superior to those lacking 
such components [10, 19]. 
 
Thus, a care model incorporating self-management support is preferable for patients with 
chronic conditions [10]. It can be hypothesized that kidney transplant recipient outcomes 
will also benefit from the incorporation of patient self-management support into related 
clinical care, as the chronic condition definition also applies to this patient group. More 
specifically, although kidney transplantation is the treatment of choice for end stage renal 
disease [20], it requires lifelong medical treatment, and coexisting morbidities are 
common [21]. In addition to regular medication taking and transplant center follow-ups, 
this includes preventing or managing risk factors for cardiovascular disease and cancer, 
coexistent morbidities or side effects of immunosuppressive therapy, and self-monitoring 
of rejection and infection signs [22, 23].  
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However, in the kidney transplant population, patient self-management has not yet been 
described, and no programs yet exist to support it. The following paragraphs therefore 
discuss patient self-management by suggesting a definition of kidney transplant recipient 
self-management. 
 
1.2. Defining patient self-management in kidney transplantation 
In general, patient self-management refers to the actions patients perform for themselves 
in daily life to manage their illness and treatment, and to avoid functional decline and 
health deterioration [10, 14, 19]. Further, patient self-management implies the patient’s 
active involvement in his/her own care. Regardless of his/her capacity for being “active”, 
over the course of the illness, a patient develops expertise at managing it on a daily basis. 
This expertise nurtures and influences daily life decisions and should therefore be 
considered as important as that of the patient’s healthcare team [12]. 
The impact of patients’ expertise regarding chronic illness self-management on health 
outcomes has been investigated in various chronic patient groups. Several Cochrane 
reviews and other research on patients with chronic obstructive pulmonary disease [24], 
diabetes [25-27], asthma [18, 28, 29], epilepsy [30, 31], bipolar disorders [32], oral 
anticoagulation [33], arthritis [34, 35] and various other chronic diseases [36] 
demonstrate associations between supporting patients’ chronic condition management 
and enhanced patient outcomes.  
For example, Lorig et al. (2008) used a randomized controlled trial to test the impact of a 
6-week community-based, peer-lead diabetes self-management program in 567 Spanish 
speaking adults with type 2 diabetes, on the participants’ health status, health behaviors, 
and self-efficacy. At 6 months, compared with standard care subjects, intervention 
subjects demonstrated significant improvements in A1C (-0.4%), health distress, 
symptoms of hypo- and hyperglycemia, and self-efficacy (p<0.05). Additionally, 
intervention subjects demonstrated improved self-rated health and communication with 
physicians, and had fewer emergency room visits (-0.18 visits in 6 months, P < 0.05). 
Furthermore, all improvements persisted to 18 months, demonstrating long-term 
effectiveness on patient outcomes [25]. 
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The effectiveness of self-management programs has also been demonstrated by others. 
Deakin et al. (2005) performed a Cochrane review to assess the effects of group based, 
patient centered training on clinical, lifestyle and psychosocial outcomes in subjects with 
type 2 diabetes. They found 11 studies involving 1532 participants. Self-management 
programs were effective in reducing glycated hemoglobin at four to six months (1.4%, 
p<0.00001), 12-14 months (0.8%, p<0.00001), and two years (1.0%, p<0.00001). Fasting 
blood glucose levels were reduced at 12 months (1.2mmol/l, p<0.00001); body weight 
was reduced at 12-14 months (1.6kg, p<0.00001); systolic blood pressure was reduced at 
four to six months (5 mm Hg, p<0.01); and diabetes knowledge was measurably 
improved at 12-14 months (p<0.00001). Furthermore, intervention subjects showed a 
reduced need for diabetes medication (odds ratio 11.8, p<0.00001) [27]. These results 
clearly demonstrate the effectiveness of self-management support using a group format. 
Expert-led self-management support, whether focusing on individuals or on groups, has 
been shown to improve patient outcomes. For example, Morris et al. (2007) summarized 
11 randomized controlled trials in patients with bipolar disorders to assess the effect of 
patient self-management support to recognize and manage early warning signs of manic, 
depressive and bipolar episodes. Six high quality studies reported on these outcomes. The 
time to the first recurrence of any type of episode (hazards ratio 0.57, 95% CI 0.39 to 
0.82), the time to a manic/hypomanic episode, the time to a depressive episode, and the 
percentage of people functioning favored the intervention group, demonstrating the 
beneficial effect of patient self-management support in patients with bipolar disorders 
[32]. Moreover, this study agreed with others [37, 38] in suggesting that patient self-
management support, including skill training components (e.g., recognizing signs and 
symptoms and acting appropriately), is effective in improving patient outcomes and may 
be superior to support limited to disease specific knowledge training. These studies 
provide clear empirical evidence that patient self-management support can effectively 
improve chronically ill patient outcomes. 
 
Despite the growing body of evidence that chronic patient populations benefit from self-
management support, most transplantation patients are still subject to an acute care 
paradigm focusing on complex immunological issues and the treatment of acute and 
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urgent post-transplantation problems. Self-management (i.e., an essential characteristic of 
chronic illness care) has not yet been described for the transplant recipient population. 
 
1.2.0. Conceptual model of the renal transplant recipients’ self-management 
The conceptual model suggested below (see figure 1) offers an overview of a possible 
renal transplant recipient self-management paradigm, along with a description of its 
transplant specific components. This model uses three components that emerged from a 
qualitative hallmark study of the work chronically ill patient groups perform for 
themselves while living with their conditions: managing the medical regimen; managing 
emotions; and managing their (new) life roles [39]. 
The kidney transplant recipient self-management model outlined here has been extended 
to offer a detailed, illness specific description of its components. More specifically, 
descriptions of specific kidney transplant recipient self-management activities were 
guided by data-based evidence in the transplant literature, and/or clinical expertise in 
transplantation care in cases where available literature was insufficient. The scope of this 
dissertation is limited to a detailed description of one of the three components, i.e., 
managing the medical regimen. Further work has to be done to describe kidney transplant 
recipient self-management of emotions and new life roles. 
 
Thus, renal transplant recipient self-management can be divided into the same three 
components as are used for other chronic illness populations (see figure 1): 1) managing 
the medical regimen, 2) managing emotions, and 3) managing (new) life roles. The 
(renal) transplant recipient’s self-management occurs individually, may affect the family 
and/or the community, and is ideally a significant part of the patient’s interaction with 
health care professionals (see outer circle). Furthermore, this self-management may start 
pre-transplantation (see arrow), with several aspects being more or less important at each 
respective stage.  
The (renal) transplant recipient must also have or acquire a set of core skills [40] (see the 
various small circles). These are: 1) problem solving: isolating problems, gathering 
information, implementing solutions, and evaluating the results; 2) decision making: 
applying information and training to distinguish medically serious symptoms from less 
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serious problems and acting appropriately; 3) resource location and skill utilization: 
navigating through health information sources and identifying the most relevant material; 
4) partnership building: appropriately discussing developments regarding the course of 
the illness with health care providers to make informed treatment decisions; and 5) action 
planning: developing and implementing short-term action plans [40]. 
 
The conceptual model for managing the medical regimen contains two inner circles. Of 
these the inner most circle may assume a more central role to the kidney transplant 
recipient’s self-management, and may have the greatest importance throughout the illness 
trajectory (e.g., immediately post-transplantation, long-term phase). For example, taking 
medications correctly is crucial at every phase. On the other hand, the outer circle 
illustrates self-management activities that ideally are incorporated before transplantation 
or immediately post-transplantation. However, if they are not ideally managed from an 
early stage, these activities may also be feasibly addressed some months post-
transplantation, after the immediate acute phase has been successfully managed. 
The conceptual model for patient self-management of the medical regimen includes four 
central components (see inner circle of managing the medical regimen in figure 1): 1) 
infection control (e.g., hygienic measures, self-monitoring for signs of infection), 2) 
monitoring vital signs (e.g., weight, blood pressure), 3) medication (e.g., a complex 
regimen of immunosuppressive drug therapy to prevent graft rejection and loss, as well as 
other medications to fight or prevent diseases, coexistent morbidities or side effects of 
immunosuppressive therapy), and 4) symptom management (e.g., self-monitoring of vital 
signs and symptoms, applying appropriate interventions for symptom alleviation). The 
outer circle of medical regimen management extends the central set to ten items: 5) no 
harmful use of substances (e.g., alcohol), 6) appointment keeping for regular follow-up 
visits, 7) non-smoking or smoking cessation (if applicable), 8) healthy eating, and 9) 
physical exercise to control weight and protect against cardiovascular disease, and 10) 
effective sun protection to guard against skin cancer. 
 
To conclude, this conceptual model for renal transplant self-management is designed to 
provide comprehensive, systematic patient self-management support in transplant clinics. 
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Such support should be oriented towards assisting kidney transplant recipients to achieve 
a complex set of objectives: to become knowledgeable about their condition, treatment 
and self-management; to develop effective decision-making strategies; to develop 
problem-solving skills for challenging situations in daily life; to interpret and integrate 
clinical recommendations into daily practice; and to change to, adhere to and perpetuate 
behaviors that support favorable short- and long-term health outcomes. 
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Figure 1: Conceptual Model for Kidney transplant recipient self-management 
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While the aim of this research program was to move towards developing a kidney 
transplant recipient self-management program, three of the seven chapters study 
medication management as a central aspect of medical regimen self-management. More 
specifically, the research focuses on measuring and enhancing medication adherence after 
kidney transplantation. Therefore, the following paragraphs provide an evidence base 
regarding adherence to self-management activities, medication adherence measurement, 
and adherence to transplantation-related interventions. 
 
1.3. Positioning adherence within patient self-management 
Patient self-management is the offspring of a care paradigm wherein patients are regarded 
as experts in managing the many tasks necessitated by their illness. Adherence, on the 
other hand, has evolved from a traditional, paternalistic care paradigm, wherein 
clinicians, assuming that they knew best, made expert decisions for patients. In the past, 
patients assumed the more passive role of simply doing what they were told by their 
clinicians. The current definition includes a measure of patient input: adherence is now 
“the extent to which a person’s behavior (taking medications, following a recommended 
diet, and/or executing lifestyle changes) corresponds with the agreed recommendations of 
a healthcare provider” [16]. The link between adherence and patient self-management lies 
in the patients’ daily application of strategies to manage adherence to the medical 
regimen. Such strategies may be based on patient knowledge regarding the medical 
regimen, and their experience with self-managing. For example, taking medication on a 
daily basis in accordance with a medication regimen requires skills inherent to patient 
self-management: problem solving, decision making, resource location and utilization, 
partnership building, and action planning [40]. 
 
1.4. The challenge of adherence to the kidney transplant medical regimen self-
management 
As illustrated in the conceptual model, kidney transplant medical regimen self-
management includes medication taking, sun protection, non-smoking or smoking 
cessation, healthy eating, physical exercise, symptom management, and infection control. 
As self-management of the medical regimen likely impacts patient outcomes, it is 
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important to have precise information regarding the risks of non-adherence. Recently, 
Dew et al. (2007) performed a meta-analysis of 147 studies in several organ transplant 
populations, and found that medical regimen non-adherence rates (i.e., cases per 100 
persons per year) in kidney transplantation ranged from low (e.g., illicit drug use: 1.0; 
alcohol use: 1.4; tobacco use: 3.3; missing clinic appointments: 4.7) to high (e.g., failure 
to take immunosuppressive medications: 35.6; following diet: 30.8) [41]. 
The following paragraphs provide more details of medical regimen self-management in 
kidney transplantation.  
 
1.4.1. Prevalence and consequences of self-management of adherence to the kidney 
transplant medical regimen  
Adherence to the prescribed medication regimen has been researched extensively in 
various chronic and acute illness populations and has been found to be a major problem: 
up to 50% of patients take medications only at levels associated with poor clinical and 
economic outcomes [42-44]. 
Medication non-adherence is also a major problem in the kidney transplant population. 
Recent literature reviews [6, 41, 45] demonstrate that non-adherence to 
immunosuppressive therapy occurs in 36 cases per 100 patients per year [41] or in an 
average of 22-28% of adult kidney transplant recipients (range 8-65%) [6, 45]. Non-
adherence accounts for 20% (range 2.5%-80%) of late acute rejections and 16% 
(range10%-64%) of graft losses.[6] The detrimental impact of immunosuppressive non-
adherence on graft outcome was recently confirmed by Takemoto et al. (2007), who 
observed a 43-46% increased risk of graft failure for subjects with imperfect adherence 
rates, suggesting that adherence be perfect for optimal graft functionality [5].  
Sub-optimal self-management is also prevalent in other aspects of the kidney transplant 
medical regimen. Limiting exposure to ultraviolet radiation, the main modifiable risk 
factor for skin cancer, requires photoprotective practices such as avoidance of sun 
exposure, use of protective clothing, and use of effective sunscreen for exposed body 
parts [22, 46, 47]. However, studies report that 25.9-62.3% of kidney transplant recipients 
do not apply any sun protection [47-49]. Further, only 18% of recipient samples usually 
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avoid the midday sun during holidays [50], and less than 50% wear protective clothing in 
the sun [47].  
The risks are unambiguous. Neglect of photoprotective practices can contribute to poor 
patient outcomes, as immunosuppressive therapy increases the risk of skin cancer after 
transplantation. It has been reported that the frequency of squamous-cell carcinoma 
increases with time post-transplantation, reaching 40-70% of patients within 20 years 
[46]. Moreover, the risk of invasive squamous cell carcinoma has been reported to be 82-
100 times greater for transplant recipients than for non-transplant populations [48, 51]. 
By year 6 post-transplantation, even after adjusting for aging, that risk factor (for patients 
aged < 50) will grow to 200 [48].  
Non-smoking, healthy eating and regular physical exercise to maintain normal weight are 
further important self-management activities in view of cardiovascular and/or cancer risk, 
as well as post-transplantation co-morbidities. Recent studies showed that 12.1%-22% of 
adult kidney transplant recipients actually smoked tobacco [52-54], while 50-60% were 
overweight or obese [54, 55]. Furthermore, despite a lack of post-transplantation exercise 
data [56], Painter et al. (2002) documented that at 1 year post-transplant only 36% of 
kidney transplant recipients enrolled in the control arm of the study performed regular 
physical exercise [57]. Despite general agreement that physical activity benefits long-
term cardiovascular health in healthy populations [58] as well as chronically ill ones, 
including kidney transplant recipients [56], evidence indicates that regular physical 
exercise generally occurs at a low rate after transplantation.  
Smoking, non-adherence to healthy diets and regular physical exercise to maintain 
normal weight contribute to morbidity and mortality after kidney transplantation, as 
cardiovascular disease, infection and malignancy are among the leading long-term causes 
of death after kidney transplantation [4]. More specifically, 30-50% and 8% of deaths of 
kidney transplant recipients with functioning grafts are due to cardiovascular disease and 
cancer, respectively [59, 60]. Moreover, kidney transplant recipients have a 3.5-5% 
annual risk of a fatal or non-fatal cardiovascular event – 50 times greater than that of the 
general population [61]. Additionally, because of the trend toward more aged, frail and 
complex end stage renal disease patients, coexisting morbidities are common in kidney 
transplant populations. A recent study analyzing data from the Canadian Organ 
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Replacement Registry, showed that 22% of the 6324 study subjects had at least one co-
morbidity (in addition to the presence of moderate or severe renal disease), with cardiac 
disease, diabetes, and malignancy the most common additional illnesses. In this kidney 
transplant population, increasing co-morbidities were predictive of poorer outcomes, a 
finding which is consistent across studies [21].  
Finally, self-monitoring of vital signs and symptoms related to graft rejection and 
infections helps to prevent graft loss and major critical incidents such as severe and/or 
systemic infections, which number among the leading causes of long-term patient death 
[4, 62]. In heart transplant patients, the prevalence of non-adherence to self-monitoring 
ranged from 22% to 59% [63], No data have been published for this aspect of the medical 
regimen among kidney transplant recipients. 
 
This literature review illustrates that aspects of medical regimen self-management largely 
impact kidney transplant recipients’ health outcomes. These findings are similar to those 
of other chronic illness patient groups (e.g., diabetes, arthritis, bipolar disorders), where 
studies have demonstrated that investing in support for patient self-management 
effectively improved clinical outcomes (e.g., HbA1C, hypo-and hyperglycemia 
symptoms, body weight, systolic blood pressure; improved symptom management) [25, 
27, 32]. All of these self-management activities therefore merit in-depth study regarding 
measurement, followed by the development of appropriate interventions. It is particularly 
important to isolate specific conditions that contribute to poor patient outcomes. 
However, the scope of this research program was limited to measuring and improving 
adherence to medication regimens.  
 
 
Chapter 3 offers a practical approach to promoting medication adherence by providing 
an overview of non-adherence correlates, consequences, and adherence enhancing 
interventions. A case example illustrates a practical implementation of a medication 
adherence enhancing intervention. 
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1.4.2. The measurement of medication regimen adherence  
As non-adherence to immunosuppressive drugs often results in poor kidney transplant 
recipient outcomes [5, 6, 45], accurate measurement of medication non-adherence is 
essential. Adherence can be measured via several direct or indirect methods, each of 
which has specific advantages and disadvantages (see table, NEJM, 2005;353;5, p.489).  
 
 
Table from NEJM, 2005;353;5, p.489 [64] 
 
In kidney transplantation, direct measure of medication adherence refer to 
immunosuppressive blood trough assay, routinely performed post-transplantation for 
most immunosuppressive drugs except azathioprin and prednisone, for which no blood 
assays are available. Some studies have used this method to measure medication non-
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adherence [65-72]. Most studies, however, have relied on indirect methods, such as 
patient self-reports (e.g., surveys, questionnaires, interviews) [65-67, 69, 72-91], 
collateral reporting [65, 69]; pharmacy refill records [5, 68, 70]; pill counts [69, 91, 92]; 
and, more recently, electronic monitoring of bottle-openings [65, 84, 88, 93-100], to 
measure non-adherence.  
Although studies have used a variety of methods [65, 68-72, 81, 84, 91], only one has 
assessed diagnostic values of kidney transplant recipients’ non-adherence measures using 
electronic monitoring (of prednisolone intake) as a reference standard [65]. For that 
study, which focused on late medication, the highest scores for both sensitivity (85.7%) 
and specificity (72.5%) corresponded to confidential interviews by the researcher. Self-
report questionnaires (i.e., the Morisky scale and medication adherence rating scale 
(MARS)), collateral reporting by nephrologists and by the researcher, and cyclosporine 
levels showed sensitivity ranging from 42.9% to 100% [65] (although the cut-off point 
necessary for 100% sensitivity misclassified half of the sample). For these collection 
methods, specificities were below 69% [65]. 
 
Given the clinical relevance of non-adherence to immunosuppressive drugs, the use of 
feasible and accurate measures is critical. This will require concise, clinically meaningful 
definitions of all domains to be measured. Once achieved, valid, cost-effective 
measurement of non-adherence will be a first step toward providing effective adherence 
enhancing interventions. 
 
 
Chapter 4 assesses the diagnostic accuracy of different methods of measuring 
medication non-adherence. The study was a sub-analysis of the SMART study 
(Supporting Medication Adherence in Renal Transplantation) [101] and included a 
sample of 249 renal transplant recipients. Diagnostic accuracy of patient self-reporting, 
clinicians’ collateral reports, and blood assay were determined using electronic 
monitoring as a reference standard. 
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1.4.3. Interventions to enhance medication adherence in adult transplant recipients 
Unfortunately, no study has yet tested a comprehensive transplant self-management 
program. Ideally, though, patient self-management support should consist of two 
components – one for disease specific knowledge and skills, and one for non-disease 
specific skills, in order to assist in behavior change [19]. Self-management programs that 
include the skill development appear to yield results superior to those focusing mainly on 
information and education [37]. With this in mind, in addition to transplant specific 
knowledge regarding medical regimen management, a comprehensive transplant self-
management program should integrate the training of core skills (e.g., problem solving) 
as defined in the conceptual model for kidney transplant recipient self-management.  
More specifically, it should assist kidney transplant recipients and their families in 
managing their medical regimen, emotions, and (new) life roles, by either acquiring or 
further developing problem solving skills for challenging situations occurring in daily 
life. It should nurture decision making skills to help patients interpret signs and 
symptoms for their medical seriousness and acuity. It can help patients develop skills and 
strategies to locate resources, navigate health information pathways, and integrate clinical 
recommendations into daily life. Finally, taking into account the individual’s home 
environment, employment situation and community, it should foster partnership building 
and action planning to adopt, adhere to and perpetuate behaviors that support favorable 
short- and long-term health outcomes. 
 
Regarding improving medication adherence in chronic-illness patient populations, based 
on the limited available evidence assessing the impact of adherence enhancing 
interventions on patient outcomes, the current consensus is that effective interventions 
should share at least four characteristics: 1) they should be derived from randomized 
controlled trials; 2) they should build upon theoretical models explaining behavior 
change, 3) they should be multidimensional, combining educational and behavioral 
interventions with social support over a sustained period; and 4) they should use a multi-
level approach simultaneously targeting risk factors on several different levels (e.g., the 
patient and the provider, or the policy maker and the health care system) [102, 103]. 
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In adult kidney and other solid organ transplant populations, evidence is scarce on 
interventions to promote medication adherence. A broad variety of interventions have 
been proposed: educational approaches [68, 104, 105], internet-based interventions [106], 
financial support programs for medications [70, 107], electronic monitoring feedback 
[108], behavioral contracting [109], and a self-medication administration program as a 
part of discharge planning [107]. The efficacy of these interventions has yet to be 
formally evaluated. However, of the studies listed here, only four used what can be 
considered appropriate bias minimizing designs. Of these, three were randomized 
controlled trials [68, 105, 108]; the fourth was a quasi-experimental (non-randomized) 
design [106]. These studies are summarized below. 
 
Dew et al. (2004) tested a 4-month multifaceted internet-based intervention program on 
mental health, quality of life, and medication adherence outcomes using a quasi-
experimental design that compared heart transplant patients and their caregivers using the 
online program (n = 20) with heart transplant patients and their caregivers receiving 
standard care (n = 40). The intervention consisted of information modules (e.g., a skills 
workshop on managing post-transplant stress and the medication regimen, a question and 
answer library, and healthy living tips) and contact modules (e.g., expert advice, 
recipients’ and caregivers’ discussion groups) meant to be used at least weekly for four 
months. Mental health, quality of life and medication adherence were assessed pre- and 
post-intervention. Mental health scores (i.e., depression, anxiety and anger-hostility, as 
measured with sub-scales of the Checklist-90 symptom data collection instrument) 
improved significantly after four months. Pre-intervention assessment revealed that 30% 
of the intervention group and 44.4% of the control group were non-adherent (p=0.461). 
These figures had decreased to 25.3% in the intervention group and 33.3% in the control 
group at 4 months post-intervention (p=0.830). While overall adherence improvement 
scores did not differ significantly between groups, more frequent use of the web-based 
intervention was linked with more enhanced intervention, suggesting that frequent use of 
the modules increased their efficacy [106].  
Hardstaff et al. (2003) used a randomized controlled trial to test the effect of electronic 
monitoring feedback on medication adherence in 48 renal transplant recipients over a 12-
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month study period. At the participants’ first clinical appointments, members of the 
intervention group (n=23) received feedback on medication taking, based on electronic 
monitoring; the control group (n=25) received none. There was no difference between the 
intervention and control groups regarding medication adherence. Over the first 3-month 
study period, adherence improved in 26% of intervention patients, worsened in 39%, and 
remained the same in 35%. In the control group, adherence improved in 20%, worsened 
in 40% and remained the same in 40%. These findings indicate that a single dose of 
feedback did not significantly improve adherence, and poorer adherence evolved over 
time in both groups. The rationale for providing feedback only once over the 12 months 
of the study remains unclear [108]. 
In a randomized controlled trial, Chisholm et al. (2001) evaluated the impact of clinical 
pharmacy services on renal transplant recipients’ immunosuppressive drug adherence. In 
addition to traditional care, the intervention patients received clinical pharmacy services, 
including medication histories and reviews to optimize medication therapy, and 
counseling and instructions from the clinical pharmacist on how to take medications 
properly. The intervention began in the first month post-transplant, and was repeated 
every month for one year. At the end of one year, the intervention group’s (n = 12) mean 
immunosuppressive drug adherence rate was 96.1% (SD=4.7%) – significantly higher 
than that of the control group (n = 12), whose mean adherence rate was 81.6% 
(SD=11.5%) (p < 0.001). Additionally, at the end of the study’s 12 month period, 75% of 
the intervention patients remained adherent, compared to 33.3% of the control group, a 
statistically significant difference (p<0.05). The authors concluded that, compared to 
traditional care, a multidisciplinary team care approach may be beneficial to enhance 
post-kidney transplantation medication adherence [68]. 
In a prospective randomized controlled trial, Klein et al. (2006) tested a similar 
intervention, i.e., the impact of a pharmaceutical care program on liver transplant 
recipients’ (N = 50) adherence to their immunosuppressive regimen for one year post 
transplantation. The intervention group (n = 24) received a combination of in-hospital 
and outpatient counseling, addressing immunosuppressive therapy, identification of drug 
related problems, discussion of vital signs and laboratory tests, adherence enhancing 
education, and a set of information tools including a diary for documenting vital signs 
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and laboratory tests. At one year post-transplant, the mean dosing adherence rate was 
significantly higher in the intervention group than in the control group (p=0.015). 
Additionally, 92% of the intervention group achieved target immunosuppressive blood 
levels, compared to 78% in the control group, demonstrating the effectiveness of the 
intervention [105].  
 
The above examples show some important limitations of the available research regarding 
the efficacy of immunosuppressive adherence-enhancing interventions. All of these 
studies can be regarded as methodological weak as assessed by the CONSORT quality 
criteria [103]. Even among the few studies using bias-minimizing designs, none use 
theory driven, comprehensive approaches testing multidimensional and multilevel 
interventions over a sustained period. However, such time-intensive designs may be, as 
evidence from non-transplant chronic and acute patient populations suggests, effective 
approaches to enhancing medication adherence - and perhaps other aspects of transplant 
recipient self-management [110-113].  
 
 
Chapter 5 is a two-center pilot RCT to test the efficacy of medication adherence 
enhancing interventions in 18 identified non-adherent renal transplant recipients over a 
nine- month study period. In addition to their usual care, for the first three months of the 
study, each intervention group member received theory driven, individualized 
educational, behavioral, and social support interventions, through a home visit and 
telephone contacts. The intervention was followed by a six-month follow-up period.  
 
 
In transplant clinics, which typically follow an acute care model, the prevailing lack of 
time restricts the support of patient self-management using enhanced human resources. 
Therefore, innovative systems need to be considered to assist transplant professionals in 
supporting patient self-management. 
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1.5. Using information technology and communication systems to support transplant 
recipients’ self-management 
E-health, i.e., health care delivery via information technology (Strategic health 
innovations in [114]), is currently entering the healthcare system, promising dramatic 
benefits for chronic illness management. Besides facilitating clinical decision making, 
collection and exchange of clinical information, reduction of medical errors, and further 
development of clinician – patient interactions, using information technology to help 
chronically ill patients become active and knowledgeable regarding their illnesses, 
treatments and self-management activities, is a key element of e-health [12]. For the care 
of chronically ill patients such as kidney transplant recipients, e-health packages have the 
potential to complement current care practices, which are characterized by insufficient 
resources, especially time, to invest in patient self-management programs. 
 
As a segment of e-health technology, computer-assisted or web based patient education 
refers to interactive computer or web based learning software (CWLS) which helps fulfill 
the general aims of e-health [115]. CWLS may impact patients’ learning both 
significantly and uniquely: educational science has demonstrated the impact of teacher 
characteristics, the school or the educational system on learners’ achievements, 
independently of pupil-related variables such as intelligence or motivation [116].  
CWLS has several advantages over traditional patient education methods. These include 
the opportunity for self-directed learning at a self-determined pace, independence from 
healthcare providers, the consistent provision of information, and the possibility to adapt 
instructional content to personal needs [115, 117]. Such advantages could be beneficial to 
assist transplant clinics in supporting transplant recipients self-management. For 
transplantation clinics, they could help users acquire transplant specific knowledge and 
technical skills as well as core skills for effective chronic illness self-management (see 
transplant recipient self-management model).  
Based on current evidence, CWLS shows promise as an effective tool to improve patient 
self-management, and thereby to enhance outcomes in chronic illness populations [38, 
118]. Murray et al. (2005) conducted a Cochrane review of 24 randomized clinical trials 
evaluating the effect of CWLS on knowledge, social support, clinical outcomes, 
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behavioral outcomes, and perceived self-efficacy, in a total of 3739 chronically ill 
patients. The project included only studies using computer-based (usually web-based) 
interactive health communication application packages, combining information with at 
least one of the following: social support (e.g., online chat rooms), decision support, or 
support for behavioral change. The meta-analysis showed significantly more 
improvement in knowledge (SMD 0.46; 95% CI 0.22-0.69; I2 52.8%), social support 
(SMD 0.35; 95% CI 0.18-0.52; I2 0%), and clinical outcomes (SMD 0.18; 95% CI 0.01-
0.35; I2 30.6%) in the intervention groups than in the control groups. Furthermore, 
patients in the intervention group showed a greater likelihood of positive effects on health 
behavior and perceived self-efficacy (i.e., the confidence in one’s ability to perform a 
certain task in a certain situation) [118]. 
The results of this review, along with other findings [38], constitute a first step in 
building up the empirical evidence that CWLS is effective in supporting self-management 
and improving health outcomes of chronic illness patients. Effective patient self-
management support in chronic illness populations needs to provide not only information 
but also interactive social support, decision-making support, and support to change 
counterproductive behavior [37]. One major goal of any such program should be to assist 
patients to gain or improve skills to manage their conditions in daily life. This emphasizes 
the need to study and develop CWLS as a health care tool. 
 
1.5.0. The development of patient self-management programs using technological 
interventions 
The development of a CWLS program to meet the demands of an effective intervention is 
challenging [117, 119-123]. Moreover, the use of a computerized system as an 
intervention tool implies that such systems need to be easy for patients to operate. This 
criterion has only recently been articulated and is referred to as system usability: “…the 
capacity of a system to allow users to carry out their tasks safely, effectively, efficiently, 
and enjoyably” (p.56) [124].  
Recently, research based usability guidelines have been published (REF), and some 
studies have reported testing the usability of their CWLS programs during the 
development phase [120, 121, 124-126]. The common finding of these studies was that 
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involving potential end users during CWLS development allowed the identification of 
many problems related to its system, including information structuring and user interface 
issues. These problems were neither anticipated nor identified by the professional 
development teams who produced them. Thus, the involvement of a group of the 
CWLS’s potential end users helped to improve its operability and efficacy. 
 
 
Chapter 6 of this research program explores the field of e-health in kidney 
transplantation by evaluating a computer assisted patient education package from the 
perspectives of clinicians and patients. The program was developed by a company, and, 
despite the lack of any previous formal evaluation, has been in use since 2001 at various 
transplantation clinics worldwide. 
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Chapter 2 
Aims of this Research Program 
 
Recent large scale analyses of renal transplant registries demonstrate a lack in significant 
improvements to long-term patient outcomes over the past decades. These findings were 
initially rather surprising, as previous long-term graft survival assumptions, based on 
projected half-lives, anticipated major progress, along the path cleared by the tremendous 
advances in short-term graft survival and immunosuppression, in the direction of long-
term outcomes [1, 2]. However, based on Kaplan Meier survival analyses the calculated 
real half-lives and other hard data now reveal that these expectations have not been 
realised [1, 2]. Such a pronounced shortfall indicates that major review papers [3-5] have 
been unable to provide complete strategies for successful long-term management of 
transplant recipients. Innovative pathways, building upon existing evidence in other 
patient populations, are therefore highly warranted to improve long-term post-transplant 
outcomes. 
Research on other patient populations shows that using a chronic care model to manage 
chronic conditions, i.e., conditions that are never completely cured [6], and that require 
open-ended periods of support to manage the illness itself, coexisting morbidities, 
treatments, or prevention of further disability [7], results in improved patient outcomes 
[7, 8].  
The chronic illness definition can also be applied to the kidney transplant population. 
Despite being the treatment of choice for end stage renal disease [9], kidney 
transplantation requires lifelong medical treatment, including medication taking and 
regular transplant center follow-ups. Steps are also necessary to prevent or manage risk 
factors for cardiovascular disease, cancer, coexistent morbidities, or the side effects of 
immunosuppressive therapy, while patients must self-monitor constantly for signs of 
rejection and infection [10, 11]. The adoption of a chronic illness model for the 
management of long-term transplant recipients may therefore be necessary to make 
progress on long-term graft survival, as it has been shown to be effective in other chronic 
illness populations [7]. Chronic illness management is characterised by continuity of care, 
partnership with patients, families, and communities, support for patients in improving 
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their self-management skills, attention to preventive measures, decision-making support 
for healthcare providers, and availability of clinical information systems [7, 8, 12, 13]. Of 
all these management characteristics, improved patient self-management is most closely 
associated with improved outcomes in chronic patient populations [14, 15]. 
 
However, to our knowledge, no comprehensive studies have been conducted on kidney 
transplant recipient self-management. Therefore, the main purpose of this research 
program was to undertake the first steps towards developing a kidney transplant recipient 
self-management program. 
 
To this end, the five objectives of this research program were: 
1) to describe the various transplant recipient self-management activities, 
synthesizing data-based knowledge and using transplant-clinic expertise (Chapter 
1); 
2) to study transplant recipient medication management (Chapter 3-5), since patient 
medication management inherits a central role both from observed transplant 
recipient self-management and from the expertise of the research group which 
embedded this dissertation; more specifically, 
3) to provide an overview of medication adherence in kidney transplantation, as well 
as a practical approach to improving non-adherence (Chapter 3), in order to 
enhance our understanding of medication adherence; 
4) to study the measurement of medication non-adherence in order to gauge the 
diagnostic accuracy of state-of-the art measures (Chapter 4); 
5) to test theory-based interventions to enhance medication adherence in non-
adherent kidney transplant recipients, with the goal of adding to the very limited 
available information based on randomized controlled trials (Chapter 5), and 
6) to evaluate a computer-based patient education program designed to enhance 
patient self-management after kidney transplantation (Chapter 6), as the 
importance of e-health technologies and communication innovations  in chronic 
illness management is growing in response to shortages of time and human 
resources. 
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Abstract 
Renal transplant recipients are expected to adhere to a lifelong therapeutic regimen 
designed to preserve long-term graft function and to reduce the risk of complications. 
Adherence to immunosuppression is a critical component of this regimen, but studies 
using electronic monitoring, the most sensitive tool currently available, have found non-
adherence rates of 20-26% in adult patients, whereas a mean prevalence of 32% has been 
reported among adolescent renal transplant recipients. Non-adherence after renal 
transplantation is an important clinical problem because even comparatively low rates of 
non-adherence are associated with increased risks of acute rejection, graft loss, reduced 
quality of life, and mortality. All members of the transplant team including hospital-based 
and community nephrologists, surgeons, nurses and therapists, should be aware of the 
possibility of non-adherence and be prepared to intervene. Promoting adherence is not 
straightforward, because risk factors for nonadherence are multifactorial and individual to 
each patient. As a result, intervention is more likely to promote lasting adherence if it is 
long term and takes place within the context of a chronic-illness management model that 
integrates behavioral, psychosocial and medical aspects of care appropriate to the unique 
needs of the individual patient. 
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Introduction 
In the last decades of the 20th century, the challenge for the renal transplant community 
shifted from preventing acute rejection early after the procedure to ensuring the long-term 
survival of the patient and graft. As the leading cause of late graft loss in patients who 
survive to return to dialysis [1], chronic allograft nephropathy has justifiably received 
much attention from investigators. Non-adherence has been less well studied, although it 
is a significant problem in clinical practice [2], and it is also a major cause of late graft 
loss [3]. 
Renal transplant recipients are expected to adhere to a lifelong therapeutic regimen 
designed to preserve long-term graft function and to reduce the risk of complications. 
Adherence to immunosuppression is a critical component of this regimen, and this article 
outlines the current understanding of non-adherence to these drugs among renal 
transplant recipients, and discusses how transplant professionals, whether based in the 
community or in hospital, can promote adherence among their patients. 
 
Understanding non-adherence 
Any discussion of non-adherence after renal transplantation is complicated by the varying 
terminologies, definitions and measurement tools used in studies of the phenomenon. The 
term “compliance” has been and is still widely used, but as this has negative connotations 
of patient passivity and professional superiority, the World Health Organization (WHO) 
has adopted “adherence”, which it defines as: “the extent to which a person’s behavior – 
taking medications, following a diet, and/or executing lifestyle changes – corresponds 
with agreed recommendations from a health care provider” [4]. 
 
The thresholds or cut-offs that differentiate between “good” and “bad” adherence among 
transplant patients remain unclear, and this is an essential area for future research given 
the association between minor deviations from the dosing schedule and an increased risk 
of adverse outcomes as observed in renal [5] and heart transplantation [6], a drug-disease 
dyad that is similar to the association between adherence and outcomes seen in 
individuals with HIV/AIDS [7]. 
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The prevalence of non-adherence to immunosuppressive drugs among renal transplant 
recipients ranges from 2 to 67% depending on the definition, case-finding and 
measurement methods used by investigators [8]. In particular, self-report, tablet counts, 
biochemical assay and pharmacy databases are likely to underestimate rates of non-
adherence compared with the more sensitive tool of electronic monitoring [4], which uses 
a pill bottle or a tablet dispenser equipped with a microprocessor that monitors the time 
and date of each opening. Studies using electronic monitoring found non-adherence rates 
of 20-26% in adult patients when non-adherence was defined as taking less than 90% of 
prescribed doses [8]. Non-adherence rates again vary depending on the study among 
adolescents (aged 11-19 years), but are consistently higher than in younger (aged < 11 
years) and adult patients, with a recent review reporting a weighted mean prevalence of 
32% [9]. 
 
The impact of non-adherence 
Although the prevalence of non-adherence among renal transplant recipients is lower than 
the mean of 50% reported among patients with other long-term conditions [10], it is 
undoubtedly an important clinical problem because even comparatively low rates of non-
adherence are associated with an increased risk of acute rejection, graft loss, reduced 
quality of life and mortality [11]. One review estimated that non-adherence by renal 
transplant recipients contributed to 16.3% of graft losses and 19.9% of late acute 
rejections, but suggested that these percentages are likely to be underestimated because 
an assessment of non-adherence is rarely routine or standardized in clinical practice [8]. 
 
The adverse consequences of non-adherence clearly have important implications for 
patients in terms of premature death or a return to dialysis, but patients who have lost 
their grafts primarily as a result of non-adherence are also less likely to be considered for 
retransplantation by health professionals [12]. Although the loss of a graft in surviving 
patients has an important impact on society in terms of the increased healthcare costs of 
dialysis as well as the loss of productivity and personal economic costs to patient and 
their families, lifetime treatment costs are higher for adherent renal transplant patients 
because of their greater life expectancy [13]. 
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This utilitarian finding should, however, be set against the 1.108 quality-adjusted life-
years gained after transplantation by adherent patients compared with non-adherent 
patients. As the incremental cost per quality-adjusted life-year of adherence is €35021 
[13] - below the benchmark used in healthcare systems that have adopted formal 
assessment of new technologies [14] – healthcare purchasers are likely to be willing to 
invest in interventions shown to improve adherence. Transplant clinicians will, of course, 
be aware of other, equally important factors justifying such an intervention, such as their 
wish to improve patient outcomes after transplantation and to ensure the optimal use of 
scarce donor organs. 
 
Correlates of non-adherence 
Effective intervention to promote adherence in clinical practice depends on the 
identification of correlates or risk factors for non-adherence, which WHO categorizes in 
relation to socioeconomics, the patient, the condition or disease, therapy or treatment, and 
the healthcare system and the health care team [4]. Under these broad categories, studies 
have identified a range of risk factors for non-adherence after renal transplantation (Table 
1). 
Chapter 3: A practical approach to improving adherence to immunosuppressive 
medication after renal transplantation 
54 
Table 1: Risk factors for non-adherence in renal transplant recipients 
Socioeconomic Adolescence 
Cost of medication 
Lack of social support, family instability, social isolation 
Patient Low self-efficacy with medication intake 
High levels of anxiety and hostility 
Perception that the evolution of the disease is a matter of 
choice 
Beliefs about illness or medication 
Lack of knowledge about the regimen 
Non-adherence before transplantation 
Condition or disease Depression 
Smoking 
Use of illegal substances 
Therapy or treatment Longer time posttransplant 
Complexity of regimen 
Patients’ subjective perception of side-effects 
Living-donor graft 
Healthcare 
system/healthcare team 
Insurance status and reimbursement of medication costs 
Authoritarian communication style and lack of 
knowledge of non-adherence by healthcare professionals 
Organizational issues, e.g. time constraints during clinical 
consultations 
Data from Denhaerynck et al, [8]. 
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Socioeconomic variables 
Apart from age and social isolation, the evidence is inconsistent that socioeconomic 
variables contribute to non-adherence after renal transplantation [8]. 
 
Patient related variables 
The contribution of the patient to non-adherence to immunosuppressive drugs has been 
well studied, possibly because patients have been seen as primarily responsible, but 
further investigation is needed to corroborate previous findings and explore other 
potential influences. The patient’s lack of knowledge about the regimen may influence 
adherence [15], but appears to be less important than the patient’s own health beliefs 
about the illness or the medication regimen; for example, believing that less 
immunosuppression is needed with a living-donor graft [11]. Studies have also found 
non-adherence in renal transplant patients to be associated with low self-efficacy with 
medication intake [15], high levels of anxiety and hostility [16], and an external locus of 
control [16, 17]; that is, the patient’s perception that the evolution of the disease is 
particularly a matter of chance. One study also found a significant positive correlation 
between pretransplant and posttransplant non-adherence [18]. 
 
Condition-related variables 
Depression and other emotional problems increase the risk of non-adherence after renal 
transplantation [19], possibly by impairing the patient’s ability to cope with their 
condition and its complex management. The absence of symptoms [20] and the presence 
of substance abuse are also associated with non-adherence [21, 22], but the latter may be 
difficult to identify, especially if illicit drug use is involved. 
 
Treatment-related variables 
There is some evidence that the cost of immunosuppressive drugs influences adherence 
[23]. Although a small, short-term, non-randomized study reported that patients were 
more likely to adhere to tacrolimus than cyclosporine when both drugs were supplied free 
of charge [24], there is little evidence that the particular immunosuppressive drug 
influences adherence except in patients who experience side-effects with corticosteroids 
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[8]. The patient’s subjective symptom distress associated with side-effects, rather than a 
particular symptom per se, is the main correlate of non-adherence [8, 25]. Health 
professionals are undoubtedly aware of patients’ concern about side-effects, but at 
present often underestimate their emotional and psychological impact [26]. 
 
Health system/health care team 
The influence of the healthcare system and transplant professionals themselves remains 
uncertain, although WHO recognizes that systems have the potential to affect patients’ 
adherence behavior, for example, by controlling health providers’ schedules, length of 
appointments, allocation of resources, fee structures, communication and information 
systems, and organizational priorities [4]. Similarly, WHO regards the quality of the 
therapeutic relationship between patient and health-care professional as an important 
correlate of non-adherence [4]. Insurance status has indeed been shown to influence 
adherence among black renal transplant recipients in the United States [27], and there are 
certainly variations in adherence rates between centers and between countries [28, 29]. 
Further investigation is needed to investigate systemic barriers to adherence and to 
highlight examples of best practice. 
 
Improving adherence 
Consensus, evidence-based guidelines recognize the clinical importance of non-
adherence after renal transplantation, and recommend that transplant professionals should 
intervene to promote adherence [30]. This implies that the long-term monitoring of 
adherence should be as important after transplantation as monitoring clinical outcomes, 
but this balance is rarely, if ever, achieved at present. Consequently, centers must invest 
in training the healthcare team to ensure that all members have the knowledge and skill to 
promote adherence. 
 
This strategy will be more difficult to implement within an acute-care medical model that 
envisages transplantation as simply a physiological intervention, in which professionals 
intervene only when the patient presents with physical symptoms. Whereas quality of life 
and life expectancy are certainly improved for most patients compared with their 
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experience of dialysis or chronic kidney disease, they continue to have a chronic 
condition, in which successful outcomes depend on professional support to promote self-
management at a very high level, including adherence to a complex, lifelong therapeutic 
regimen [31]. 
 
In adopting a chronic-disease model of care that integrates behavioral and psychosocial 
aspects of management, transplant professionals can draw on the experience of clinical 
colleagues and investigators in other therapeutic disciplines such as diabetes or heart 
failure, which demonstrates that non-adherence is a complex phenomenon and all 
contributory factors need to be understood and addressed. All patients should be 
monitored for correlates or risk factors for non-adherence, which should be targeted with 
an appropriate intervention that is tailored to the individual patient. Such an approach is 
more likely to promote lasting adherence if it is: high-dose in that it involves appropriate 
combinations of educational, affective and behavioral interventions shown to improve 
adherence; multi-level in that patients, professionals and organizations are targeted; and 
is applied in the long term [4, 32]. 
 
Specific interventions 
Most studies among renal transplant patients have investigated interventions designed to 
promote adherence through education, behavioral interventions, and psychosocial 
support. It should, however, be borne in mind that to date only one pilot randomized 
controlled study has sought to evaluate the benefits of a multifaceted program designed to 
promote adherence among adult renal transplant patients who were identified as non-
adherers [33]. A prospective study, however, reported significantly more quality-adjusted 
treatment-free days among patients receiving an experimental posttransplant care 
program that was designed to improve kidney transplant recipients’ quality of life [34]. 
There was also significantly better adherence at follow-up among a subgroup of patients 
using a web-based medical regimen workshop as part of a prospective study that aimed to 
improve mental health among heart transplant patients and their families [35]. 
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Patient education 
Clinical guidelines emphasize the role of specific educational programs to address non-
adherence after renal transplantation [30]. Patient education is likely to be most effective 
if it is consistent and is individualized to each patient, taking into account cognitive, 
educational, developmental and intellectual capacities. It is also important for transplant 
professionals to check that the patient has understood the information correctly, and to 
reinforce educational messages regularly (for example, “refresher courses” for long-term 
patients). 
 
Whereas many centers provide verbal and written education, it may also be useful to take 
advantage of specific self-medication education before discharge [36], and computer-
based learning tools such as the Organ Transplant Information SystemTM (Roche 
Pharmaceuticals, Basel, Switzerland) or the Organ Transplant Visual Med SchedulerTM 
(Wyeth, Madison, New Jersey, USA), although it should be borne in mind that the 
efficacy and content validity of such programs has yet to be assessed in prospective 
studies. Furthermore, education and greater knowledge do not in themselves promote 
adherence – health professionals are themselves notoriously non-adherent to medication – 
and behavioral change is strongly influenced by inappropriate health beliefs, such as the 
perception that immunosuppressive drugs are unnecessary [37]. 
 
Behavioral interventions 
Interventions that empower patients and enable them to participate in their care are likely 
to contribute to adherence. Simple suggestions include the use of medication aids such as 
calendar packs, electronic reminder systems, and advice on how to adapt the regimen to 
the patient’s lifestyle and combine medication taking with routine activities such as 
mealtimes [38]. Electronic monitoring devices such as pill bottles or dispenser packs not 
only provide the most accurate measure of adherence [4], but also offer the transplant 
professional the opportunity to identify the timing of and possible triggers for non-
adherence. This knowledge can then be shared with the patient when agreeing on an 
individualized program to improve adherence and during follow-up provide feedback, 
Chapter 3: A practical approach to improving adherence to immunosuppressive 
medication after renal transplantation 
59 
which in positive circumstances can provide the patient with mastery experience thus 
improving self-efficacy[33] (see Table 2). 
Chapter 3: A practical approach to improving adherence to immunosuppressive medication after renal transplantation 
60 
Table 2: Case history 
After being found to be non-adherent to cyclosporine on electronic monitoring, A.W., a 42-year-old female kidney transplant 
recipient, was invited and agreed to enter the SMART trial [33]. This prospective randomized study evaluated the benefits of a 
multifaceted education program in improving adherence among adult renal transplant recipients. 
On assessment, risk factors for non-adherence by A.W. were: 
? Misconceived health beliefs that “posttransplant drugs last for more than 24 hours in the body” and that “immunosuppressive 
medication can be so strong that it can cause harm to the body” [20]. 
? An extremely busy personal schedule without routine except for regular meals. 
? A low level of perceived social support in taking her medication. 
 
SMART study interventions consisted of a home visit and three subsequent telephone calls at monthly intervals, designed to support 
self-efficacy, i.e. the individual’s confidence in performing a specific behavior such as medication taking even when in taxing 
situations. All intervention patients received feedback on their medication intake based on electronic monitoring printouts and a 
refresher course on their medication management. The intervention nurse also suggested individualized behavioral and social support 
interventions depending on each patient’s risk factors for non-adherence. 
 
A.W. chose to adapt her medication taking to her daily routine, by taking her cyclosporine with her in the morning when leaving for 
work and by taking the evening dose at dinnertime. Because of her husband’s own busy schedule, she decided not to involve him in 
the management of her medication, and she received counseling about her mistaken health beliefs. 
 
These interventions were applied during the first intervention month, and during the regular telephone calls A.W. received feedback 
on her adherence based on the results of electronic monitoring. This was designed to support her self-efficacy, verbally reward her 
improved adherence, and to explore whether she perceived the interventions as helpful. 
 
Based on electronic monitoring, A.W.’s medication taking adherencea improved from 87.5% at baseline to 100, 97 and 96.6% after 
one, 2 and 3 months’ intervention, respectively. Her timing adherenceb improved from 61.4% at baseline to 90.0% at on month, but 
declined to 69.7% at month 2 and 62.1% at month 3, a result explained by the greater priority given by A.W. to medication taking 
rather than the timing of the dose. 
a (Number of events recorded during the monitored period) / ( Number of prescribed doses during the monitored period) x 100. 
b (Number of near optimal interdose intervals) / (total amount of observed intervals) x 100. 
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Affective interventions 
Psychosocial support is an essential aspect of chronic disease management designed to 
reduce the risk of non-adherence associated with depression and other emotional 
problems [31]. Furthermore, any behavioral change designed to promote adherence 
depends on a trusting, cooperative relationship between health professionals and patients 
that takes account of patients’ attitudes, intentions and health beliefs [39]. Such a 
relationship is especially important when managing adolescent transplant recipients. 
Clinicians should use a non-judgmental, supportive, non-accusatory, information-
intensive approach to this age group, and special care should be taken when transferring 
younger patients from pediatric to adult follow-up. This is because normal developmental 
issues are the main driver for non-adherence among teenagers (striving for normalcy, 
issues over autonomy, peer pressure), who characteristically rebel against the advice of 
authority figures such as parents and health professionals [9]. 
 
Increased dosing frequency is associated with non-adherence among renal transplant 
patients [28], and therefore simplifying the regimen of immunosuppressive and other 
drugs may improve adherence. It could be hypothesized that immunosuppressive drugs 
such as sirolimus that have a longer half life are more forgiving in view of non-
adherence, however, this needs to be further substantiated by research. Transplant 
patients should be asked specifically about distressing symptoms related to side-effects 
because they may be reluctant to bother their hard-pressed transplant professionals about 
these issues during a short consultation at a busy clinic. Although many patients are 
prepared to trade off cosmetic side-effects in order to retain their transplant [26], health 
professionals should reinforce adherence by offering ameliorating treatment or advice 
(for example, treatment of acne or dental referral to manage gingival hyperplasia). 
 
Immunosuppression should always be tailored to the needs of the individual patient, and 
switching to another drug in the same class [40] or using a steroid-sparing regimen [41] 
may also help to reduce side-effects. There should always be a clear rational for adjusting 
the regimen, however, and it is essential to ensure that the patient continues to receive 
sufficient immunosuppression to prevent acute rejection. Furthermore, any adjustment to 
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the regimen should only be implemented after confirming that the side-effect will 
respond to this approach and after counseling the patient about the possible long-term 
implications for graft survival. Even then, it may not be practical to change the regimen 
in well-established patients, for example, some patient may experience intractable 
symptoms with late corticosteroid withdrawal [42]. 
 
Conclusion 
Non-adherence is common after renal transplantation and has important clinical 
consequences. All members of the transplant team – hospital – based and community 
nephrologists, surgeons, nurses and therapists – should be aware of the possibility of non-
adherence and be prepared to intervene. Promoting adherence is not straightforward 
because there is no single solution that applies to every patient, and centers must be 
prepared to invest the resources necessary to enable professionals and patients to 
implement an intensive, multilevel, long-term strategy that systematically promotes 
adherence as part of a chronic disease model of posttransplant care. 
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Abstract 
Valid assessment of immunosuppressive therapy non-adherence (NAH) is vital: NAH is 
associated with negative transplantation outcomes. We studied the diagnostic accuracy of assay, 
patient self-reports and clinicians’ collateral reports and composite adherence scores using 
electronic monitoring (EM) as a reference standard.  
This cross-sectional study included a convenience sample of 249 adult kidney transplant 
recipients (Ktx) (female: 43.4%; mean age 53.6 (SD: 12.7), median 7 years (IQR: 9 years)) post-
Ktx. NAH was assessed using EM over 3 months (i.e., reference standard), assays of 
cyclosporine, tacrolimus, mycophenolat-mofetil, patients’ self-reports, and clinicians’ collateral 
reports. The constructed composite adherence score included assay, self-reports, and collateral 
reports. 
NAH’s prevalence across the measurement methods was: EM: 17.3%; assay: 33% (cyclosporine: 
25.8%; tacrolimus: 35.1%; mycophenolat-mofetil: 40.2%;); self-report: 12.4%; collateral reports: 
23.9%, and composite adherence score: 38.9%, respectively. The composite adherence score and 
collateral reports showed the highest and lowest sensitivities to NAH (72.1% and 15.8% 
respectively). Specificity was highest for collateral reports of at least three clinicians (93.1%). 
Likelihood ratio of a positive test was 2.74 for composite adherence score. 
No measures showed high sensitivity alongside high specificity. Combining measures increased 
diagnostic accuracy, indicating the relevance of combined measures for clinical and research 
purposes. 
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Introduction 
Favorable kidney transplantation (Ktx) outcomes depend on strict adherence to 
immunosuppressive medication (IS) regimens [1-4]. However, empirical evidence shows an 
average non-adherence prevalence of 28% (range: 8-65%) among adult recipients [1], accounting 
for 20% (range: 2.5-80%) of late acute rejections, and 16% (range: 10-64%) of all graft losses 
[1]. NAH is also associated with poor economic outcomes [5]. 
 
Non-adherence measurement 
The wide range of NAH prevalences results partly from differences in methods of case definition 
and measurement. Assessment methods can be direct or indirect, and offer varying levels of 
sensitivity [6]. 
Direct measures include observation of medication intake and biological assay of drug levels or 
drug metabolites in the blood or urine [6]. Observation verifies adherence, yet necessitates direct 
patient–clinician encounters, and does not elucidate medication intake dynamics [7], which is 
also true for biological assay [8]. Although drug monitoring depicts the patient’s state of 
immunosuppression, results are influenced by the drug’s half-life, metabolic rates, drug-drug 
interactions, and white coat adherence (i.e., greater adherence before a clinical visit) [9-11]. In 
the Tx literature, few studies [12-14] have included direct measures, such as IS assays, to 
measure NAH. 
Indirect measures include patient self-reporting, collateral reports from family members or 
clinicians, prescription fills, pill counts, and electronic monitoring [6]. Self- and collateral 
reporting are uncomplicated, inexpensive, and feasible in most clinical settings, but are prone to 
recall and social desirability response bias. Collateral reporting depends on the reporter’s 
familiarity with the patient [8, 10]. The fill frequency of prescriptions requires complete 
pharmacy records – problematic when patients use a number of non-networked pharmacies [7, 8, 
15]; and pill counts (i.e., pills dispensed, remaining, and prescribed) are invalidated when patients 
hoard or discard drugs [8, 10]. In summary, state-of-the-art measures such as self-reporting, 
collateral reporting, prescription refills, and pill count usually under-represent non-adherence, 
while providing little information about individual medication-related behavior [7, 10]. 
In Tx, for over a decade, most studies have relied on patient self-reporting (e.g., surveys, 
questionnaires, interviews) [3, 16-28] to measure NAH, whereas collateral reporting [13], 
pharmacy refill records [29, 30], and pill counts [31] have rarely been used. 
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Reference standards allow superior validity. Electronic monitoring (EM) provides detailed 
information on individual medication use [32], and is therefore recommended as the reference 
standard for medication non-adherence [33]. EM involves fitting a pill bottle with a 
timer/counter, which continuously records every cap opening date and time. Data can be 
uploaded to a computer to chart individual medication use dynamics [8, 32]. However, EM can 1) 
be used incorrectly [34], 2) negatively impact established adherence routines [35], or 3) improve 
normal adherence through an intervention effect [36]. If applicable, these factors affect the 
validity of EM. Nevertheless, EM’s superiority in assessing non-adherence makes it a logical 
reference standard. Recently, a growing number of studies in Tx [13, 37-42] shifted to EM to 
assess NAH.  
 
Diagnostic values of state-of-the-art measures 
To our knowledge, only one study has assessed diagnostic values of Tx NAH measures using an 
EM (of prednisolone intake) reference standard [13]. A confidential interview by the researcher 
focusing on late medication use showed the highest sensitivity (85.7%) and specificity (72.5%). 
Self-report questionnaires (i.e., Morisky scale and medication adherence rating scale (MARS)), 
collateral reporting by nephrologists and by the researcher, and cyclosporine levels showed 
sensitivity ranging from 42.9% to 100% [13] (the cut-off point necessary for 100% sensitivity 
misclassified half of the sample). Specificities were below 69% [13]. These findings match those 
regarding other chronically ill patient populations using EM reference standards [43-47]. 
Given the clinical relevance of IS non-adherence, this study aimed to assess the diagnostic 
accuracy of assay, self-reporting, collateral reporting, and composite adherence scores as 
compared to EM in adult Ktx recipients.  
 
Materials and Methods 
This report complies with the Standard of Reporting Diagnostic Study (STARDS) criteria [48]. 
Design, sample and setting 
This study was a sub-analysis of the SMART (Supporting Medication Adherence in Renal 
Transplantation) study [49]. Figure 1 shows the various adherence measures as assessed over 
several data collection time points to determine point and period prevalence of non-adherence to 
IS. 
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Figure 1: Design of the study 
 
 
 
 
 
 
 
 
 
 
 *   0   3   * time (months) 
 
Measurement points are shown as triangles, the various adherence measures as squares. 
Measurement point 2 = inclusion into study 
EM = electronic monitoring 
* We collected the first assay result before inclusion into the study, and the last after finishing the 
3-months study period. 
 
 
The convenience sample of the study included adult Ktx recipients, all more than one year post 
Ktx, taking IS, having given written informed consent (see Denhaerynck, et al. [37] for a 
complete description of inclusion and exclusion criteria), and having a valid EM dataset for 
analysis (procedure described elsewhere [37]). The valid EM data criteria allowed the exclusion 
of patients who had failed to use EM correctly for their daily IS use. No significant differences 
existed between self-reported adherence of included and excluded patients. The study was 
performed at two Swiss outpatient teaching hospital clinics. See Denhaerynck et al. [37] for study 
setting details.  
 
Variables and measurement 
Demographic and clinical variables are reported elsewhere [37].  
Non-adherence measures. We used the MEMS®-V TrackCap electronic monitoring (EM) system 
(Aardex, Ltd., Zug, Switzerland) as our reference standard to assess NAH to IS taken twice daily, 
consisting of the smallest pill size (for easier storage). We defined EM period prevalences (three 
2 1 3 4
Self-reporting 
EM (3 months) 
Assay Assay Assay Assay 
Collateral reporting 
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month study period) as: taking adherence (the percentage of prescribed doses taken), dosing 
adherence (the percentage of days with correct dosing), timing adherence (the percentage of 
inter-dose intervals within 25% of the prescribed interval) and drug holidays (the number of 
periods without drug intake exceeding 60h or 36h for a once and twice daily regimen, 
respectively, standardized over 100 days) [37]. Because evidence suggested statistically 
significantly higher adherence at the start of the study [50], we excluded the first 35 days of EM 
monitoring. We defined the following cut-off (i.e., EM algorithm) to assign Ktx recipients to the 
non-adherent subgroup: < 98% taking adherence and/or at least one drug holiday. Evidence from 
previous research, showing that minimal deviations from the dosing schedule were associated 
with increased risk of late acute rejection episodes in adult heart [42] and renal [2] transplant 
recipients, supports this stringent cut-off. 
Assay: Trough blood levels for the drugs monitored by EM (i.e., cyclosporine (CsA), tacrolimus 
(FK), mycophenolat-mofetil (MMF) and sirolimus (Rapa)) were performed using Fluorescence 
Polarization Immunoassay, High Performance Liquid Chromatography or Microparticle Enzyme 
Immunoassay technology at four time points (see figure 1). No assay for Azathioprin (Aza) and 
Prednisone (Pred) is available, therefore recipients regarding whom these drugs were monitored 
were not included in this part of the analysis. We specified a therapeutic range for each drug 
based on clinical guidelines used at the renal transplant program of the Basel University Hospital. 
Independently of the medication regimens, which included multi-drug combinations (dosage 
adjusted to compensate for interactions between calcineurin inhibitors and MMF), measured 
therapeutic ranges were 100-150ng/ml for CsA, 2-4ng/ml for MMF, and 5-10ng/ml for FK and 
Rapa. To determine therapeutic ranges, we also considered individual target trough blood levels 
(e.g., as in response to clinical issues such as rejection and toxicity status) as noted in the medical 
records. To combine several trough blood level results we assessed the non-therapeutic blood 
assay variability of CsA, MMF, and FK using the following approach (adapted from [51]). The 
percentage of sub-therapeutic CsA assay variability was calculated by dividing the number of 
sub-therapeutic CsA (< 100ng/ml, or lower than individual target) blood assay levels through the 
total number of CsA levels analyzed per patient. The percentage of supra-therapeutic CsA 
variability was determined by dividing the number of supra-therapeutic (> 150 ng/ml or higher 
than individual target) blood assay levels by the total number of CsA levels analyzed per patient. 
The percentage of sub- and supra-therapeutic CsA blood assay variability was a combination of 
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both. Accordingly, non-therapeutic blood assay variability for MMF and FK was determined 
using MMF and FK specific values indicated in the clinical guidelines (see above).  
Self-report: At inclusion, we measured self-reported non-adherence to IS with the Siegal scale 
[52] by asking recipients in a non-accusatory, information-seeking way [13, 53] about how often, 
over the preceding four weeks, they 1) had not taken their IS, 2) had forgotten to take there IS, 3) 
had not taken their IS because they believed that they did not need them, and 4) had reduced the 
prescribed amount of IS. A 7-point scale assessed their answers, ranging from 0 (never) to 6 (on a 
daily basis). No validity data have been reported; however, this instrument has been used in 
previous studies [52, 54, 55]. Any reported non-adherence on any of the four items served as a 
cut-off criterion [52, 54] to split the sample into an adherent and a non-adherent group. 
Collateral report: Non-adherence was also assessed using collateral reports by transplant 
clinicians. During the first study month, we asked 7 physicians, 4 nurses, and 2 medical assistants 
involved in the follow-up care of Ktx recipients to score recipients’ adherence in one of three 
categories: good, fair, or poor. We developed the following algorithm to combine responses of 
different clinicians per recipient. A recipient received a score of 0 if all clinicians estimated 
his/her adherence as good. A recipient received a score of 1, 2, 3, or 4 according to the number of 
clinicians (i.e., one to four clinician/s) estimating his/her adherence as fair. A recipient received a 
score of 5 if even one clinician estimated his adherence as poor, independently of the estimations 
given by other clinicians. Thus, perfect adherence corresponded to a total score of 0, increasing 
uncertainty with regard to adherence to a score of 1 to 4, and non-adherence to a score of 5. 
Composite adherence score. We developed two composite adherence scores combining various 
methods of non-adherence assessment. Composite adherence score 1 (CAS 1) consisted of self-
reported non-adherence and/or collateral-reports (scores 1 to 5). Composite adherence score 2 
(CAS 2) used self-reported non-adherence and/or collateral-reported non-adherence (score 1 to 5) 
and/or non-therapeutic blood assay variability. 
Data collection 
Data collection took place between June 2001 and January 2004. One of four research assistants, 
none of whom belonged to the therapeutic team, approached each recipient who met the inclusion 
criteria during their regular yearly check-up visits to the outpatient clinic serving the two study 
centers. The research assistant informed prospective subjects about the purpose of the study, 
explained the use of the EM system, disclosed that the cap would monitor medication taking 
behavior, obtained written informed consent, and gathered demographic data and self-reported 
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adherence via a structured interview. Participants received a stamped, addressed envelope with 
which to return the EM cap after 3 months of monitoring. If necessary, they were reminded by 
mail to return the EM device. We used Powerview® (Aardex Ltd.) hardware and software to 
upload the EM data from the device. A research assistant approached the clinicians individually 
to assess collateral reports of IS non-adherence for each patient. These face-to-face and oral 
interviews were performed within one month after the start of the data collection. Self-reports and 
collateral reports were collected before results of EM were available. Data collectors, blinded to 
the results of other NAH measurement methods, retrieved assay values and selected clinical data 
from the medical records.  
 
Ethical considerations 
In addition to the regional ethical committees of “Beider Basel” and Aarau, the Swiss federal 
ethics committee approved this study in 2001. 
 
Data analysis 
Correlation analysis (Spearman’s rho) assessed the associations between the different 
measurement methods. We performed receiver operating characteristic (ROC) analysis for two 
purposes: 1) to dichotomize ordinal (i.e., collateral reports) and interval scaled variables (i.e., 
assay) in relation to sensitivity and specificity, in order to develop a 2x2 table for calculating 
diagnostic values; and 2) to calculate the area under the curves (AUC) as a measure of 
discriminant power. For information on dichotomizing other variables (i.e., EM and self-reports) 
see “Variables and measurement”. Diagnostic values of assays, self-reports, collateral reports, 
and composite adherence scores using EM as the reference standard were determined using 
sensitivity, specificity, accuracy, positive and negative predictive value, and likelihood ratios of 
positive and negative tests. 
All calculations were performed using the SPSS® version 14.0 statistical software package 
(SPSS® Inc. Headquarters, Chicago, Illinois, USA). We considered a p value < 0.05 as 
statistically significant. 
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Results 
Sample 
The SMART study [37] invited 413 eligible Ktx recipients to participate. Of the 356 (86%) who 
accepted, 291 (82%) agreed to electronic monitoring, while 65 (18%) choose to fill in 
questionnaires only. Of the 291 EM consenting recipients, seven (2%) dropped out (3 never 
started; 3 did not return the monitor; 1 died). Of the remaining 284, 35 (12%) did not follow EM 
guidelines. Thus, 249 Ktx recipients met the inclusion criteria and provided usable EM data for 
this study (see Figure 1: sample profile in [37]). Table 1 lists selected demographic and clinical 
sample characteristics. 
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Table 1: Demographic and clinical sample characteristics (N=249) 
 Mean (SD) 
Median [iqr] Frequency (%) 
Range 
Sex 
Women 
Men 
 
43.4 
56.6 
 
Age (in years) 53.6 (12.7) 25-81 
Caucasian (n=245) 96.4  
Nationality 
    Switzerland 
    Other European countries 
    Other Countries 
 
83.5 
14.0 
2.5 
 
Education (in years) 
    Primary school (6/7 years of school) 
    Secondary school (8/9 years of school) 
    Additional schools 
 
13.3 
47.0 
39.7 
 
Marital status 
    Single/Divorced/Widowed 
    Married/Living with partner 
 
17.7/9.6/5.2 
67.5 
 
Not enough resources to pay for medications 19.5  
Graft type 
    Deceased donor 
    Living related 
    Living unrelated 
 
60.6 
26.9 
12.0 
 
 
 
 
Time post transplantation (in years) 7 [9] 0.92-34 
Dosage of immunosuppressive drugs (mg/day) 
    Cyclosporine (n=166) 
    Mycophenolat-Mofetil (n=117) 
    Tacrolimus (n=42) 
    Sirolimus (n=15) 
    Azathioprin (n=76) 
    Prednisone (n=62) 
 
200 [75] 
1500 [1000] 
5 [3] 
2.5 [2.8] 
100 [50] 
7.5 [2.5] 
 
75-450 
500-3000 
1-8 
1-8 
25-200 
2.5-20 
Frequency of immunosuppressive drug (IS) intake 
per day 
 
2 [0] 
 
1-4 
Number of medication to take (other than IS) 4 [4] 0-12 
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Prevalences of non-adherence 
Electronic monitoring. A total of 22,535 subject days were electronically monitored, with a mean 
monitored time of 91 days (SD = 8.9, range 43-127). Mycophenolat-Mofetil (40.9%) was 
monitored most often, followed by Cyclosporine (36.0%), Tacrolimus (14.6%), combined 
Azathioprin and Prednisone (7.3%), Sirolimus (0.8%), and Prednisone alone (0.4%) respectively. 
The mean three-month prevalence of EM adherence parameters were: taking adherence 98.4% 
(SD = 5.07), dosing adherence 96.2% (SD = 8.7), timing adherence 91.9% (SD = 15.1), and drug 
holidays 0.2 days (SD = 1.7). The EM algorithm yielded a non-adherence prevalence of 17.3%. 
 
Assay. We collected a median of 4 (range: 1-17) blood samples per recipient (n = 230), with a 
total of 940 samples of the monitored CsA, MMF, FK, and Rapa. Table 2 shows the three-month 
prevalence of blood assay variability for the monitored drugs. The prevalence of non-adherence, 
as reflected by all immunosuppressive blood levels (cut-off > 52%), non-therapeutic FK blood 
levels (cut-off > 29%), supra-therapeutic MMF blood levels (cut-off > 29%), and non-therapeutic 
CsA blood levels (cut-off > 70%), were 33%, 35.1%, 40.2%, and 25.8%, respectively. 
 
 
Table 2: Assay result variability (in %)* 
 Sub-therapeutic 
blood levels Median 
(Q1, Q3), Range 
Supra-therapeutic 
blood levels 
Median (Q1, Q3), 
Range 
Non-therapeutic 
blood levels 
Median (Q1, Q3), 
Range 
All immunosuppressive 
drugs (n = 230) 
20.0 (0.0, 50.0), 0.0-
100.0 
0.0 (0.0, 33.3), 0.0-
100.0 
45.0 (25.0, 66.7), 
0.0-100.0 
Cyclosporine (n = 89) 25.0 (0.0, 63.3), 0.0-
100.0 
0.0 (0.0, 25.0), 0.0-
100.0 
40.0 (25.0, 75.0), 
0.0-100.0 
Mycophenolat-Mofetil (n = 
102) 
20.0 (0.0, 42.5), 0.0-
100.0 
17.8 (0.0, 50.0), 0-
100 
50.0 (32.1, 67.9), 
0.0-100.0 
Tacrolimus (n = 37) 12.5 (0.0, 25.0), 0.0-
80.0 
0.0 (0.0, 22.5), 0.0-
87.5 
25.0 (0.0, 43.1), 
0.0-87.5 
* see variables and methods section for definitions 
Note: Sirolimus accounted for too few cases (n = 2) and was therefore not separately explored. 
Chapter 4: Diagnostic accuracy of measurement methods to assess non-adherence to 
immunosuppressive drugs in kidney transplant recipients 
77 
Self-report. Table 3 lists the prevalence of self-reported non-adherence at inclusion into the study, 
assessed via the Siegal Scale. The prevalence of reported non-adherence on any of the four items 
was 12.4%. 
 
 
Table 3: Self reported non-adherence (Siegal scale *) (N=249) 
 Once a 
month 
Every 2 
weeks 
Item 1 
In the last four weeks, how often have you not taken your 
immunosuppressive medications? 
7.4%  3.7% 
Item 2 
In the last four weeks, how often have you not taken your 
immunosuppressive drugs because you forgot them?  
7.3% 2.0% 
Item 3 
In the last four weeks, have you ever not taken your immunosuppressive 
drugs because you believed you did not need them?  
- 0.4% 
Item 4 
In the last four weeks have you ever reduced the amount of your 
immunosuppressive drugs because you believed you did not need as 
much of them as your doctors thought?  
- 0.4% 
Any self-reported non-adherence: 12.4% 
* Participants could answer the items with never (corresponds to being adherent), once a month, 
every 2 weeks, every week, every 3 to 4 days, every other day; every day 
 
 
Collateral reports. For a total of 213 patients at the two centers, seven physicians, 4 nurses, and 2 
medical assistants provided 1278 estimates. Of these, 72% were rated as “good”, 13.4% as “fair”, 
0.3% as “poor”, and 14.3% as “missing values”. Non-adherence as assessed by clinicians’ 
collateral reports from two centers ranged from 0.9% to 23.9% (see table 4). 
The prevalences of collaterally reported non-adherence were 45.1% (cut-off ≥ 1 clinicians’ 
responses of fair or lower adherence), 21.1% (cut-off ≥ 2 clinicians’ responses of fair or lower 
adherence), and 8.5% (cut-off ≥ 3 clinicians’ responses of fair or lower adherence). 
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Table 4: Non-adherence as assessed by clinicians’ collateral reports from two centers (n = 213) 
Participants with Frequency 
1 clinician’s response of fair adherence 23.9% 
2 clinicians’ responses of fair adherence 12.7% 
3 clinicians’ responses of fair adherence  5.2% 
4 clinicians’ responses of fair adherence  2.3% 
1 clinician’s response of poor adherence  0.9% 
 
 
ROC analysis 
Area under the curves (AUC). The largest AUC’s for drug assay variability ranged from .554 for 
non-therapeutic CSA assay variability, to .567 for supra-therapeutic MMF, and to .667 for non-
therapeutic FK (only FK shown, see figure 2). Other blood assay variability revealed no 
discriminating power (e.g., AUC of sub-therapeutic MMF = .436, figure not shown). Area under 
the curve for clinicians’ collateral reports was .596 (see figure 3). More specifically, AUC’s of 
individual clinicians’ collateral reports ranged from .457 to .625 (figures not shown). 
 
Figure 2: Receiver operating characteristic of non-therapeutic blood variability of tacrolimus (n = 
37) 
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Area under the curve = .667 (95% CI = .432 - .902) 
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Figure 3: Receiver operating characteristic of clinicians’ collateral reports (N = 213) 
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Area under the curve = .596 (95% CI = .492 - .699) 
 
 
Diagnostic values 
Figure 4a-b shows the diagnostic values of assays, self-reports, clinicians’ collateral reports, and 
the composite adherence scores as compared to the EM algorithm. 
 
Chapter 4: Diagnostic accuracy of measurement methods to assess non-adherence to 
immunosuppressive drugs in kidney transplant recipients 
80 
Figure 4a: Selected diagnostic values of assays, self-reports, clinicians’ collateral reports, and 
composite adherence scores as compared to EM algorithm. 
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EM (electronic monitoring) algorithm (i.e., reference standard) = taking adherence < 98% and/or 
at least 1 drug holiday 
IS = immunosuppressive drugs; CsA = cyclosporine; MMF = mycophenolat-mofetil; FK = 
tacrolimus 
SR = patient self-reports; CR = clinicians’ collateral reports; CAS 1, CAS 2 = composite 
adherence scores 
Pr NAH = prevalence of non-adherence 
* non-therapeutic blood assay variability; ** supra-therapeutic blood assay variability 
1 = Patients were classified as non-adherent if they had at least 1 clinician’s response of fair or 
lower adherence. 
2 = Patients were classified as non-adherent if they had at least 2 clinicians’ responses of fair or 
lower adherence. 
3 = Patients were classified as non-adherent if they had at least 3 clinicians’ responses of fair or 
lower adherence. 
A = Patients were classified as non-adherent if they self-reported non-adherence and/or had at 
least 1 clinician’s response of fair or lower adherence. 
B = Patients were classified as non-adherent if they self-reported non-adherence and/or had at 
least 4 clinicians’ responses of fair or lower adherence. 
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C = Patients were classified as non-adherent if they self-reported non-adherence and/or had at 
least 1 clinician’s response of fair or lower adherence and/or had non-therapeutic blood assay 
variability (cut-off > 69%). 
D = Patients were classified as non-adherent if they self-reported non-adherence and/or had at 
least 4 clinicians’ responses of fair or lower adherence and/or had non-therapeutic blood assay 
variability (cut-off > 69%). 
 
 
Figure 4b: Selected diagnostic values of assays, self-reports, clinicians’ collateral reports, and 
composite adherence scores as compared to EM algorithm 
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LH+ = likelihood ratio of a positive test result; PV- = negative predictive value; LH- = likelihood 
ratio of a negative test result; AUC = area under the curve; PV+ = positive predictive value; Pr 
NAH = prevalence of non-adherence 
Further abbreviations, see legend figure 4a 
 
 
Sensitivity. Composite adherence score 2 resulted in the highest sensitivity (72.1%) followed by 
composite adherence score 1 (62.8%), collateral reports (57.9%), and supra-therapeutic MMF 
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assay variability (60.0%) Table 5a presents a cross tabulation of the results of the CAS 2 
alongside the results of the EM algorithm.  
 
 
Table5a: Cross tabulation: composite adherence score 2 using EM algorithm 
                                                                                                     EM algorithm 
CAS 2 Non-adherent patients Adherent patients 
Non-adherent patients 31 118 
Adherent patients 12 88 
CAS 2 = composite adherence score 2 (cut-off = self-reported non-adherence and/or at least 1 
clinician’s response of “fair” or lower adherence and/or non-therapeutic assay variability) 
EM = electronic monitoring 
EM algorithm = taking adherence < 98.0% and/or at least 1 drug holiday 
Sensitivity = 31/43 x 100%= 72.0% 
 
 
Specificity. Collateral reports of three clinicians’ responses of fair adherence showed 93.1% 
specificity, followed by self-reports and composite adherence score 1 (cut-off = self-reported 
non-adherence and/or at least 4 clinicians’ responses of fair or lower adherence) which gave 
equal values of 89.8%, followed in turn by collateral reports of at least 2 clinicians’ responses of 
fair or lower adherence (81.1%). Table 5b presents a cross tabulation of the results of the CR 
alongside the results of the EM algorithm.  
 
Table 5b: Cross tabulation: collateral reports using EM algorithm 
                                                                                                     EM algorithm 
CR Non-adherent patients Adherent patients 
Non-adherent patients 6 12 
Adherent patients 32 163 
CR = collateral reports (cut-off = at least 3 clinicians’ responses of “fair” or lower adherence) 
EM = electronic monitoring 
EM algorithm = taking adherence < 98.0% and/or at least 1 drug holiday 
Specificity = 163/175 x 100%= 93.1%  
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Likelihood ratios of positive tests. Composite adherence score 1 (cut-off = self-reported non-
adherence and/or at least 4 clinicians’ responses of fair or lower adherence) resulted in a 2.74 
likelihood ratio of a positive test (LH+), indicating that a patient whose test results indicated non-
adherence was almost three times more likely to actually be non-adherent than a patient with no 
such findings. LH+ results of at least three clinicians’ collateral reports, self-reported non-
adherence and non-therapeutic FK assay variability (cut-off > 29%) ranged from 2.3 to 1.9. Table 
5c presents a cross tabulation of the results of the CAS 1 with the results of the EM algorithm.  
 
 
Table 5c: Cross tabulation: composite adherence score 1 using EM algorithm 
                                                                                                      EM algorithm 
CAS 1 Non-adherent patients Adherent patients 
Non-adherent patients 12 21 
Adherent patients 31 185 
CAS 1 = composite adherence score 1 (cut-off = self-reported non-adherence and/or at least 4 
clinicians’ responses of “fair” or lower adherence) 
EM = electronic monitoring 
EM algorithm = taking adherence < 98.0% and/or at least 1 drug holiday 
Likelihood ratio of a positive test (LH+)  = Sensitivity / (1 - Specificity) = (12/43) / (1- 
(185/206)) = 2.74 
 
 
Validation of the different methods 
Table 6 shows the correlations (spearman’s rho, two-tailed) between the different methods. 
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Table 6: Spearman’s rho correlation table of all measurement methods 
 Sb  Sp Nt SR EM A TA DA TiA DH 
/100d 
CR CAS1 CAS2 
Sub-therapeutic 
blood levels (Sb) 
1.000 -.447** .527** -.046 -.021 -.041 -.017 -.004 .019 .109 -.078 -.325* 
Supra-therapeutic 
blood levels (Sp) 
 1.000 .379** -.122 .026 -.045 -.076 -.118 -.003 -.023 -.097 -.218** 
Non-therapeutic 
blood levels (Nt) 
  1.000 -.140* -.041 -.101 -.073 -.084 .042 .063 -.155* -.657** 
Self report (SR)    1.000 .150* .099 .091 .331* -.133* -.075 .965** .493** 
EM algorithm (EM 
A) 
    1.000 .683** .645** .481** -.513** -.140* .197* .135* 
Taking adherence 
(TA) 
     1.000 .706** .438** -.348** -.166* .129* .168** 
Dosing adherence 
(DA) 
      1.000 .667** -.340** -.146* .119 .155* 
Timing adherence 
(TiA) 
       1.000 -.262** -.093 .333** .289** 
Drug holiday / 100 
days (DH/100d) 
        1.000 .049 -.122 -.148* 
Clinicians 
collateral report 
(CR) 
         1.000 -.121 -.036 
Composite 
adherence score 1† 
          1.000 .511** 
Composite 
adherence score 2†† 
           1.000 
* Correlation is significant at the .05 level (2-tailed) 
** Correlation is significant at the .01 level (2-tailed) 
† Composite adherence score 1 = self-reported non-adherence and/or clinicians’ responses of fair or lower adherence (CAS1 B, see legend 
figure 4 for details) 
†† Composite adherence score 2 = self-reported non-adherence and/or clinicians’ responses of fair or lower adherence and/or non-therapeutic 
blood assay variability (CAS2 D, see legend figure 4 for details) 
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Assays. Significant correlations were found between non-therapeutic assay variability and self-
reported non-adherence rrho = -.140 (p < .05). 
Self-reports. Self-reported non-adherence significantly correlated with EM drug holidays, the EM 
algorithm, and EM timing adherence, ranging from rrho = -.133 (p < .05) to rrho = .331 (p < .05). 
Clinicians’ collateral reports. Clinicians collateral reports correlated significantly with the EM 
algorithm rrho = -.140 (p < .05), EM dosing adherence rrho = -.146 (p < .05), and EM taking 
adherence rrho = -.166 (p < .05). 
Composite adherence scores. Composite adherence score 1 correlated significantly with EM 
taking adherence, non-therapeutic blood levels, the EM algorithm, and EM timing adherence 
(ranging from rrho = .129 (p < .05) to rrho = .333 (p < .01)). Composite adherence score 2 
correlated significantly with the EM algorithm, EM drug holidays/100d, EM dosing adherence, 
EM taking adherence, and EM timing adherence (ranging from rrho = .135 (p < .05) to rrho = .289 
(p < .01)). 
 
Discussion 
This study is one of the few studies assessing the diagnostic accuracy of state-of-the-art measures 
of non-adherence to immunosuppressive regimens (assays, self-reports, clinicians’ collateral 
reports, and composite adherence scores) as compared to electronic monitoring. The prevalences 
of non-adherence in our sample match those reported in other studies [1]. Furthermore, the data 
of this study reflect the wide variation of prevalences of non-adherence with respect to various 
measurement methods and specific cut-off points.  
The study findings suggest that the most valuable measurement approach in view of detecting the 
highest rate of non-adherent patients (i.e., high sensitivity) was the use of a composite adherence 
score, drawing non-adherence information from patient self-reports, nurses’ or physicians’ 
collateral reports and non-therapeutic assay results. However, this measure concurrently showed 
low specificity, indicating its value for “screening” (i.e., a first step) rather than diagnosis. Other 
work with HIV infected patients also showed that a composite adherence score achieved the 
highest sensitivity [56]. As in other studies investigating diverse patient populations [44-47], our 
study found low sensitivity to non-adherence when only one state-of-the-art measure was used to 
indicate non-adherence. Poor sensitivity of individual measures means that they failed to identify 
many truly non-adherent patients. 
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Our data suggest that high specificity can best be achieved by combining several clinicians’ 
reports of “fair” adherence, by combining several methods, or by assessing patients’ self-reports. 
The combined value of several clinicians’ reports regarding uncertain adherence to medications is 
noteworthy: thus far, collateral reporting by a single clinician has been regarded an invalid 
method of assessing medication non-adherence [7, 45, 57]. 
Although non-therapeutic FK assay variability, non-therapeutic CsA assay variability and supra-
therapeutic MMF assay variability provided useful levels either of specificity or of sensitivity, 
nowhere did we find consistency regarding both, nor could consistent cut-off values, sub-
therapeutic, non-therapeutic or supra-therapeutic assay values be determined across the various 
immunosuppressive regimens, even after multiple sensitivity analyses (data not presented). We 
therefore emphasize that this study’s blood assay findings should be treated with caution when 
used to infer information about patients’ non-adherence status. 
The study revealed unexpectedly low inter-method correlations. When methods were combined, 
however, correlations improved. These findings suggest that, while the applied methods did not 
overlap strongly in measuring medication non-adherence as a whole, each method still functioned 
as a partial indicator. For maximum validity, then, EM should be combined with other methods, 
rather than used as a reference standard to evaluate them. 
 
Limitations 
First, this study did not clinically validate the EM algorithm, which was used as the reference 
standard, because of the lack of prospective clinical outcomes. However, we performed 
sensitivity analysis with various EM cut-offs which resulted in stable diagnostic values (data not 
presented), which supports the accuracy and robustness of the presented results. Furthermore, in a 
previous study investigating a sample of heart transplanted recipients more than one year after Tx 
on a CsA regimen [54], this EM algorithm showed discriminative power concerning partly 
prospective data of late acute rejection episodes.  
Second, it is possible that participant selection bias occurred in the following ways: 1) non-
adherent recipients may have been more likely to refuse EM monitoring, although we found no 
evidence of this (i.e., no differences in non-adherence state-of-the-art measures between EM 
participants and eligible EM non-participants [37]); and 2) due to recent changes in Swiss law, it 
is not possible to determine whether the sample was representative of the kidney-transplanted 
population of the two centers. The law requires informed consent – which was not available in 
Chapter 4: Diagnostic accuracy of measurement methods to assess non-adherence to 
immunosuppressive drugs in kidney transplant recipients 
87 
this study – to collect demographic and clinical data on patients who refuse to participate. 
Therefore, the findings of this study can not be generalized. 
Third, it is possible that the study suffered from a bias of survivor selection by including only 
recipients more than one year post-transplantation. Recipients with severe non-adherence may 
already have been ineligible for this study due to a nonfunctioning graft. 
Fourth, the results of the state-of-the-art measurement methods and reference standard were not 
read blinded. However, the criteria used to classify participants as non-adherent were not prone to 
subjective interpretation but based on a predefined algorithm (reference standard) and ROC. 
Therefore, it is unlikely that the lack of blinding influenced the reading of the results of either the 
state-of-the-art measures or the reference standard.  
Fifth, in our study, while EM measured a three-month period, assay ranged beyond this period, 
and self- and collateral reporting dealt with non-adherence prior to the start of EM. However, we 
did not consider these non-identical measurement times as problematic: previous work suggested 
that, barring the occurrence of a major event, adherence to medication should be a stable behavior 
[58]. 
Finally, this study assessed patients’ adherence to only one immunosuppressive drug. Therefore, 
the findings might not reflect adherence to the full immunosuppressive regimen. However, 
empirical evidence suggests that non-adherence should be comparable between several 
medications [59], yet research should substantiate this in Tx. 
 
To conclude, our findings add to the limited evidence concerning the diagnostic accuracy of 
adherence measurement with immunosuppressive regimens using EM as a reference standard. 
Using EM as a reference standard depends on two conditions: 1) an assumption that the patient is 
not systematically deceiving the monitoring process; and 2) the use of measures to address 
validity threats to EM [34], (e.g., differentiation between adherence to medication taking and 
adherence to EM guidelines). This study showed that none of the state-of-the-art measures 
resulted in both high sensitivity and high specificity, when compared to EM. Despite the clear 
shortcomings of using any single measure, the most valid measure to correctly identify NAH was 
to combine the results of several tests, each of which included consistent known limitations. This 
implies that, for clinical practice any information suggesting non-adherence, regardless of its 
source, should be taken seriously as a possible non-adherence indicator, and should lead to a non-
accusatory and non-threatening non-adherence assessment, followed, if applicable, by offering 
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appropriate interventions. In individual patients with non-adherence indications, EM may then be 
used to monitor medication taking behavior, because it provides data that are helpful for both 
problem detection and encouraging mastery experience in medication taking [50]. In the absence 
of a perfect method, further research is clearly warranted, however, to focus specifically on 
combined measurement methods, which have considerable potential to enhance our 
understanding of medication non-adherence detection and measurement. 
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Abstract 
Background. Although non-adherence to an immunosuppressive regimen (NAH) is a major risk 
factor for poor outcome after renal transplantation (RTx), very few studies have examined non-
adherence intervention in this context. This pilot randomized controlled trial (RCT) tested the 
efficacy of an educational-behavioral intervention to increase adherence in non-adherent RTx 
patients. We also assessed how NAH evolves over time. 
Methods. Eighteen RTx non-adherent patients (age: 45.6±1.2 yr; 78.6% male) were randomly 
assigned to either an intervention group (IG) (N=6) or an enhanced usual care group (EUCG) 
(N=12), the latter receiving the usual clinical care. The IG received one home visit and three 
telephone interviews. We assessed NAH through electronic monitoring (EM) of medication 
intake during a nine-month period (three months intervention, six months follow-up).  
Results. Five of 18 patients withdrew. Inclusion in the study resulted in a remarkable decrease in 
NAH in both groups over the first three months (IG χ2 =3.97, df=1, p=.04; EUCG χ2=3.40, df=1, 
p=.06). The IG showed the greatest decrease in NAH after three months, although this did not 
reach statistical significance (at 90 d, χ2=1.05, df=1, p=.31). Thereafter, NAH increased 
gradually in both groups, reaching comparable levels at the end of the six-month follow-up (i.e., 
at nine months). 
Conclusion. Our findings suggest an inclusion effect. Although the intervention in this pilot RCT 
appeared to add further benefit in medication compliance, a lack of statistical power prevented us 
from making a strong statistical statement. 
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Introduction 
A recent systematic review of the literature showed that 28% of adult renal transplant recipients 
report that they do not adhere to their immunosuppressive regimen [1]. Several studies have 
shown that patient non-adherence to immunosuppressive drugs detrimentally affects the short- 
and long-term outcomes of renal transplantation [2-4]. Twenty percent of late acute rejections 
and 16% of graft losses have been associated with non-adherence to the immunosuppressive 
regimen (NAH) [1]. This evidence highlights the importance of adherence-enhancing 
intervention as a possible pathway to improve the clinical outcome of renal transplantation. The 
value of this pathway is not well recognized in the medical literature. Indeed, a recent review of 
strategies aimed at enhancing long-term outcome after renal transplantation did not consider the 
potential value of adherence enhancing interventions [5].  
Scarce evidence exists on interventions that promote medication adherence in populations 
receiving solid organ transplants. Several possible interventions have been described: educational 
approaches [6], behavioral contracting [7], financial support programs for drugs [8], feedback on 
medication intake via electronic monitoring [9], and self-medication administration program as 
part of discharge planning [10]. The efficacy of these interventions is yet to be formally tested. 
To date, the only study to assess the efficacy of a non-adherence intervention was that of Dew et 
al. [11]. This study used a non-equivalent comparative design to test the efficacy of a 
multifaceted web-based intervention program in improving mental health, quality of life, and 
adherence. Although Dew et al. found no improvement in overall adherence scores, they did find 
that patients using the web-based intervention more often had high adherence scores, suggesting 
that increased participation in the intervention resulted in increased adherence. To our 
knowledge, no randomized controlled trials (RCT) have been carried out with the aim of testing 
the efficacy of adherence-enhancing interventions for medication regimens following solid organ 
transplantation.  
Two meta-analyses [12, 13] and two structured literature reviews [14, 15] have described the 
efficacy of adherence-enhancing interventions for medication regimens in non-transplant, 
chronic- and acute-care populations. The most effective approaches are multilevel, targeting more 
than one risk factor over a sustained time. Multilevel interventions are integrated not only at the 
patient-provider level but also at organizational and health-care system levels. Targeting risk 
factors of non-adherence includes approaches that use a combination of educational, cognitive 
behavioral, and social support interventions to change modifiable socioeconomic, patient-, 
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treatment-, condition-, and health-care team-related factors that are linked to non-adherence [16]. 
For instance, a knowledge deficit can be remedied by educational interventions. Patient education 
alone, however, is not an effective adherence-enhancing strategy [12-15]. A major determinant of 
NAH in transplant populations is low self-efficacy [17, 18]. This refers to a person’s confidence 
in successfully performing a specific behavior (e.g., medication taking), even in taxing situations 
[19]. Self-efficacy can be targeted by specific interventions such as having the patient experience 
mastery experiences, role modelling, verbal persuasion, and decreasing physiological arousal 
[20]. Because non-adherent patients are three times higher at risk for depression [21], depression 
should be treated as part of the adherence-enhancing intervention. In summary, it is the 
combination of interventions over a sustained time that seems to be most effective in preventing 
non-adherence [22]. 
Scant evidence exists concerning the effectiveness of adherence-enhancing interventions in solid 
organ transplant populations. Given this, and the evidence that non-adherence is a major risk 
factor for poor outcome after transplantation, the purpose of this pilot RCT was to test the 
efficacy of a three-month adherence-enhancing intervention in non-adherent renal transplant 
recipients. Adherence was assessed at the end of the intervention and at the end of a six-month 
follow-up (i.e., nine months after initiation of the intervention). 
 
The alternative hypotheses guiding this study were following: 
? Patients in the intervention group will show a lower chance of being non-adherent compared 
to the enhanced usual care group at the end of the intervention period (three months) and at 
the end of the six months follow-up (i.e. nine months), respectively.  
? The chance of being non-adherent will increase in patients in the intervention group after the 
end of the intervention (i.e. between three months and nine months follow-up) 
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Patients and Methods 
Design 
This study was a RCT. Three months of intervention treatment took place followed by six months 
of follow-up. 
 
Sample and Setting 
Inclusion and exclusion criteria 
To be included in the present study, the patient had to be non-adherent to their 
immunosuppressive regimen (see below), at least 18 yr old; to be in follow-up at the University 
Hospital Basel, Switzerland, or at the Cantonal Hospital, Aarau, Switzerland; to speak German or 
French; to be literate; to have undergone kidney transplant surgery at least one year prior to the 
study; to be able to self-administer immunosuppressive drugs; to reside within a 180-km radius of 
Basel; and to provide written informed consent to participate in the RCT.  
Patients included in this study were previously identified as being non-adherent to their 
immunosuppressive regimen in a previous study based on the three months of EM [17]. Period 
prevalences of non-adherence were calculated and eligibility status for the present study was 
determined by predefined algorithm (Table 1). The algorithm’s stringent cut-off for non-
adherence was based on previous research showing that minimal deviations from dosing schedule 
of the immunosuppressive regimen were associated with an increased risk for poor clinical 
outcome [2, 23].  
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Table 1: Non-adherence algorithm 
< 98% taking adherence and / or one or more drug holidays 
EM a 
parameters 
Operationalization 
Taking 
adherence  
Number of events recorded during the monitoring period / Number of 
prescribed doses during the monitoring period x 100 
Drug holiday No medication intake 
? 36 hours for a twice daily dosing regimen (Cyclosporine, 
Mycophenolat-Mofetil, Tacrolimus, Sirolimus), or 
? > 60 hours for a once daily dosing regimen (Azathioprin/Prednison®) 
Timing 
adherence  
Number of near optimal inter-dose intervalsa / Total number of observed 
intervals x 100 
a The near optimal inter-administration interval was calculated as the time interval between events 
(pill-bottle-cap openings) within 24 ± 6 hours of the previous event for a once-daily dosing 
regimen, within 12 ± 3 hours for a twice-daily dosing regimen, and within 8 ± 2 hours for a three-
times-a-day dosing regimen (thus accounting for 25% of the optimal dosing interval). 
EM, electronic monitoring 
 
 
Patients were excluded if they lacked mental clarity based on clinician’s appraisal, could not read 
forms or EM printouts with at least corrective lens, or had no telephone service at home. 
 
Setting 
This study was carried out in Switzerland, which has a compulsory health insurance system. The 
standard health-care package covers transplantation, the majority of costs for follow-up care, and 
immunosuppressive medications. However, patients pay premiums, franchise, and 10% of out-of-
pocket costs for hospital and outpatient care and for prescribed drugs. Most patients resided in 
Switzerland, a country about half the area of Maine (USA), thus minimizing the travel distance to 
the transplant center. 
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Randomization procedures 
Patients were randomly assigned to an enhanced usual care group (EUCG) or an intervention 
group (IG), stratified by site, using a 2:1 randomization scheme in favor of the enhanced usual 
care group (23). A person independent of the research team performed the assignments using 
random number tables. Group assignment was sealed in envelopes until the end of the study.  
 
Variables and measurement 
Demographic and clinical data 
We used demographic and clinical data that were part of the baseline measurements from our 
previous descriptive study [17]; these data were acquired from the patients’ original medical files.  
 
Adherence to immunosuppressive regimen 
We measured adherence to the immunosuppressive regimen by EM throughout the nine-month 
study (i.e., three months intervention and six months follow-up). EM consisted of gathering 
digital data about a patient’s medicine-taking habits. A microelectronic circuit contained in the 
bottle cap of the patient’s pill bottle registered the date and time of each bottle opening. Data 
were downloaded to a computer, which in turn generated lists and graphics of medication-taking 
habits [24]. Although an indirect method, EM is more sensitive in measuring non-adherence 
compared to other tools, such as self-reporting, blood testing, or pill counts [25-28]. Moreover, 
because it measures both if and when the patient took their medication, “drug holidays” (i.e., no 
medication intake for more than 36 or 60 hours, depending on dosing regimen and drugs) were 
easily detected. Immunosuppressive drugs for the present study were repackaged into individual 
EM containers labeled with each patient’s regimen, according to current GMP and GCP 
guidelines. To guarantee the chemical stability of the medication, we left the pills in their drug 
blisters.  
 
Consistent with ethical guidelines, we informed patients that the EM measured medication intake. 
We also gave oral and written instructions on how to use the bottle correctly. Because using the 
EM can be challenging in daily life, patients were allowed to note deviations from EM guidelines 
on a custom form. An example deviation would be removing a dose from the EM bottle before 
leaving the house and ingesting the medication at a later time. At the end of the nine months, we 
assessed reliability and validity of EM data by interviewing patients over the telephone using 
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structured questions based on previously developed methodology [23]. We also asked patients 
about practical problems with using EM in daily life and adherence with EM guidelines [23]. 
A research associate aware of the group assignments downloaded the EM data using 
Powerview® software (Aardex Ltd., Zug, Switzerland). We made adjustments to each patient’s 
data based on entries on the patient’s note form (see above), and then we calculated EM 
parameters (see below). 
 
Enhanced usual care  
Patients in the EUCG received the usual kind of care that outpatients receive during post-
transplant follow-up care. The ethics committee overseeing the study (see below) requested that 
we inform the treating physicians if their patients were identified as being non-adherent. They 
also asked us to inform the treating physicians if their patients’ scores on the Beck Depression 
Inventory (BDI; score of >15 on BDI), completed during the previous study, suggested moderate 
or severe depression or suicidal ideation [29]. We asked the treating physicians to note the 
intervention(s) they performed after learning of their patients’ non-adherence.  
 
Intervention 
Patients in the IG received enhanced usual care plus one home visit after inclusion in the study, 
followed by three follow-up calls, one at the end of the month for three consecutive months. 
Table 2 summarizes the different parts of the intervention. 
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Table 2: Elements of the Intervention 
Type of 
intervention 
Elements 
Behavioral: self- 
efficacy 
Initiating mastery experience using EM printouts 
Verbal persuasion: motivation & empowerment 
Role modeling using EM printouts of adherent patients 
Decreasing physiological arousal especially in view of symptom distress 
Other behavioral 
interventions 
Cues: Linking medication taking with a routine behavior 
Reminders: e.g. alarm signal (watch, mobile phone) 
Reducing complexity of medication regimen 
Referral to psychiatrist: BDI scores of >15 
Educational: 
tailored + 
individualized 
Refreshment course: 
-Assessment of knowledge status; 
-Discuss purpose, intake and monitoring of medication 
Problem solving strategies: Address possible coping strategies with specific 
issues related to medication taking 
Social support Involvement of significant others in: 
-Preparation and reminding of medication administration 
-Filling prescriptions 
-Assisting in deciding to contact a HCW when problems occur 
EM, electronic monitoring; BDI, Beck Depression Inventory; HCW, health-care workers. 
 
 
The core of the intervention was aimed at increasing patients’ self-efficacy in taking their 
medication consistently. To accomplish this, we used EM printouts for problem detection, proxy 
goal setting (i.e., definition of short-term goals), and regular targeted feedback [20]. EM printouts 
tabulated and graphed each patient’s daily adherence dynamics (intake and regularity of 
medication taking). We implemented additional educational, behavioral, and/or social support 
interventions during the home visit (see below) that were based on an individualized assessment 
of reasons for non-adherence and/or information on determinants of non-adherence gathered 
during the previous study [17] and new information gathered during the home visit.  
 
Chapter 5: Supporting medication adherence in renal transplantation (SMART): a pilot RCT to 
improve adherence to immunosuppressive regimens 
102 
Home Visit 
The patient, and if applicable a family member, participated in the home visit. First, we assessed 
daily medication management by observing where medications were located and how the patient 
or family member handled the medications, and by questioning. This was followed by a 
discussion of non-adherence issues we detected in the EM data from the previous study. We 
discussed possible factors associated with non-adherence (e.g., knowledge of adherence status, 
problematic illness representations, and side-effects from the immunosuppressive therapy). We 
made a special effort to respect the patients’ perspective, acknowledging that they are in charge 
of their own self-management. 
 
Next, the intervention nurse, patient, and family members together discussed possible adherence-
enhancing interventions the patient and family perceived to be feasible and acceptable. All 
patients received self-efficacy interventions consisting of four elements: 1) developing mastery 
experiences in taking medications correctly (e.g., setting and successfully meeting proxy goals 
for the next month that were feasible for implementing a specific behavior —see Telephone 
Follow-up below); 2) participating in role modeling (e.g., using EM printouts of comparable RTx 
patients showing the targeted behavior); 3) verbally persuading by the intervention nurse; and 4) 
addressing negative effects of physiological arousal, if applicable (e.g., discussing strategies to 
cope with the side effects of immunosuppressive drugs).  
 
In addition to self-efficacy interventions, the intervention nurse applied individualized 
intervention strategies that were derived from specific non-adherence–related dynamics. These 
included a refreshment course on 1) purpose of the medication; 2) taking of the medication; 3) 
monitoring of the medication; 4) assessment of side effects and symptom experience; and 5) 
individualized problem-solving strategies for managing immunosuppressive drugs in daily life 
based on the patients’ specific needs. Possible behavioral interventions included cueing (e.g., 
placing pill bottle next to patient’s purse as a reminder to bring the medication on trips, or taking 
medications with meals or at bedtime); explicit reminders (e.g., alarm using a watch or mobile 
telephone to signal time to take the medication); and reducing the complexity of medication 
regimen, if possible. Social support interventions included family members, friends, or 
colleagues involved in medication management (e.g., preparing patients' medication for 
administration, reminding patients to be punctual about taking their medications, filling 
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prescriptions, and assisting in contacting a health-care worker when problems arise). The 
protocol stipulated that patients with moderate and severe depressive symptoms (BDI score > 15) 
would be referred to a psychiatrist for further evaluation. 
 
The intervention nurse, patient, and family defined proxy goals aimed at increasing adherence for 
the next month. Before leaving the patient’s home, a telephone connected interface (Homelink) 
was installed, allowing the patient to send their monthly EM data to the research team. 
 
Telephone follow-up 
After the home visit, we contacted the patients by telephone three times, once at the end of the 
month for three consecutive months. Before each telephone follow-up session, we sent EM 
printouts to each patient by fax, mail, or email so that the patient could review them and refer to 
them during the telephone follow-up interview. The researcher began each session by briefly 
assessing the patient’s current health status (e.g., infections, hospital admission) and/or by asking 
the patient about any recent special events (e.g., holidays, work, and family situation). Next, the 
researcher discussed the EM printout with the patient. Improvement in the patient’s adherence 
was rewarded by positive comments to promote in the patient mastery experiences. Non-
adherence was addressed in a supportive, non-accusatory manner, with the aim of determining 
the patient’s reasoning for failing to take the medication. The researcher and patient discussed the 
efficacy of adherence strategies the patient used that month. If the patient’s strategies were 
ineffective, the researcher suggested alternative strategies for the upcoming month. The nurse 
attempted to engage the patient in role modeling, if deemed appropriate. The telephone call 
concluded by setting proxy goals to increase adherence for the next month. The home visits and 
telephone contacts were tape-recorded to maintain data integrity and for qualitative data analysis. 
At the end of the intervention period, the researcher asked the patients which intervention(s) they 
remembered and perceived as being most helpful. 
 
Data collection procedures 
A Master’s degree-level nurse, not part of the transplant team, recruited patients by telephone. 
The nurse explained the goals of the study and obtained oral informed consent for participation. 
We also obtained written informed consent through follow-up mail. After randomly assigning 
patients to the IG or the EHCG, we informed them by telephone to which group they were 
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assigned. We also verbally verified their actual immunosuppressive regimen, so that the hospital 
pharmacy could prepare the EM bottles accordingly. For the EUCG, we mailed the EM pill 
bottles, and for the IG, we hand delivered the bottles to the patients’ homes.  
After we obtained written informed consent from each patient, we notified the treating physicians 
by letter about the non-adherence status of their patients (see above). Patients received a new 
supply of immunosuppressive drugs by mail every 3 months during the 9 months of EM 
monitoring. At the completion of the study, we interviewed the patients to assess the validity and 
reliability of the EM monitoring.  
 
Data analysis 
Daily EM events were used as the unit of analysis for descriptive and inferential statistics. These 
data were binary (i.e., dose was taken or not taken). 
 
Descriptive statistics 
Demographic and clinical variables were expressed, as appropriate, in frequencies, mean and 
standard deviations (normally distributed and interval scaled variables), and median and 
interquartiles ranges (not normal distributed and ordinal scaled variables). We used the Statistical 
Software Package of Social Science (SPSS®, Chicago, IL, USA) version 11.1.  
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Inferential statistics 
We used Intention-to-Treat principles for analysis. To test whether adherence levels differed 
between the study groups at three months and nine months, we designated a binary variable to 
each patient’s daily adherence and modeled the probability of non-adherence using a corrected 
logistic regression analysis (Generalized Estimating Equations) [30]. We tested for a possible 
difference in temporal evolution of non-adherence from baseline in both study groups by 
specifying an interaction term between study group and time. Modelling was done with the 
GENMOD procedure in SAS 8.1 statistical software. 
 
Statistical significance was set at p < 0.05. For exploratory purposes, we also fit a generalized 
additive model with a logit link function, because this technique enabled us to visually detect 
possible nonlinear trajectories of the predicted logarithmized odds (log odds) on non-adherence 
in both study groups. Log odds are algebraically transformed probabilities that enable the use of 
linear functions in logistic regression analysis. Generalized additive models allow one to explore 
how the chances on non-adherence evolve nonlinearly over time, which in turn allows one to test 
whether the assumption of linearity underlying logistic regression analysis corresponds with 
reality. We calculated the sample size required to achieve 80% statistical power using the SAS 
“UnifyPow” macro. This was done post hoc and was based on the χ2. 
 
Qualitative assessment of intervention effect 
We either noted responses to the open-ended question at the end of the intervention, or tape 
recorded and transcribed them. We used content analysis techniques [31] to do a preliminary 
analysis of these data. 
 
Human subjects’ consideration 
The study was approved by the ethics committees of the University Hospital Basel and the 
Cantonal Hospital of Aarau, as well as by the Federal Ethics Committee of Switzerland. Besides 
giving oral and written informed consent for participation, IG patients gave additional oral 
informed consent to tape-record during the home visits and telephone interviews. We informed 
the treating physicians of the subjects’ non-adherence and depression status, as required by the 
ethics committee.  
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Results 
Of 273 renal transplant recipients participating in the previous descriptive study [17], 43 patients 
were categorized as being non-adherent (Table 1), all of whom were invited to participate in the 
present study (see CONSORT flow diagram: Figure 1). Eighteen patients (37%) agreed to 
participate. Of these, six were assigned to the intervention group (IG), and 12 were assigned to 
the EUCG. Self-exclusion reasons ranged from the patients’ denial of a non-adherence problem 
to the patients’ perception that EM was too burdensome to use daily. Participants (n=18) and 
those declining to participate (n=25) were similar in age (t = 1.254, df = 41, p = 0.217); gender 
(χ2=2.185, df=1, p = 0.139); time since transplantation (t = -.378, df = 41, p = 0.707); medication 
taking adherence (U=207.5 [25/18], p = 0.667); and dosing adherence (U=213.5 [25/18], p = 
0.777). They differed significantly in timing adherence and drug holidays, with participants 
showing less adherence in taking their medication at the correct time (median: 67.4% vs 82.6%; 
U=130.5 [25/18], p = 0.02), and fewer drug holidays per 100 d of monitoring (median: 0 vs. 1; U 
= 134 [25/18], p = 0.017). Patients in the intervention group and enhanced usual care group were 
comparable in view of age, time post-transplantation and baseline adherence levels. 
 
Five patients dropped out during the study (three EUCG and two IG). One EUCG patient 
eventually failed to independently manage his medication because of cognitive decline, and two 
lost interest in participating. One IG patient decided to withdraw before the start of the home 
visit, one lost the EM device at the end of the study. Thus, complete data were available for 10 
EUCG and five IG patients at three months follow-up (end of intervention period, and for nine 
EUCG and four IG at nine months follow-up, respectively (see CONSORT flow diagram: Figure 
1). 
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Figure 1: Consort diagram 
Eligible patients*  n = 43
Refusals
n = 25
Included        
n = 18       
Intervention Group             
n = 6
Enhanced Usual Care Group              
n = 12
Drop-outs   n = 2
Reasons: Cognitive decline;
Lost interest in participation
n = 10
Patients monitored EM    n = 273
* Eligibility based on algorithm (see Table 1)
Randomization 2:1
3 m. Drop-outs   n = 1
Reason: Lost interest in 
participation 
Drop-outs   n = 1
Reason:  
Lost interest in participation
9 m. Drop-outs   n = 1
Reason: 
Lost EM device
Reasons:
Denial of non-adherence
EM too burdensome
n = 9
n = 5
n = 4
 
 
Evolution of non-adherence within the IG and EUCG 
To understand the evolution of non-adherence over the course of the study, we calculated a 
smoothed plot of the nonlinear trajectories of the predicted chance of non-adherence (Figure 2).  
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Figure 2: Nonlinear regression lines, modeling the temporal evolution of non-adherence during 
the baseline measurement, the three-month intervention, and the six-month follow-up. The 
probability of being adherent versus being non-adherent (averaged over patients within a group) 
is plotted. Only the IG patients received a specific intervention (see text). 
 
 
 
 
 
Non-adherence declined remarkably in both groups during the first three months of the study (IG 
χ2=3.97, df=1, p=.04; EUCG χ2=3.40, df=1, p=.06). Although the chance of non-adherence 
gradually increased after this initial decline, by the end of the nine-month study, non-adherence 
had leveled off to a probability that was lower than that calculated at the start of the study, 
especially for the IG patients. This gradual increase in non-adherence for the IG patients after the 
three-month intervention suggests, however, that in order for the full effects to persist, 
intervention procedures must continue for longer than three months. 
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Evolution of non-adherence between IG and EUCG 
Although the IG patients’ chance of being non-adherent during the first 3 months decreased more 
than the EUCG patients’ chance, as shown by the smoothed plot of Figure 2, this group 
difference did not reach statistical significance (χ2=1.05, df=1, p=0.31). This was also the case at 
nine months (χ2=0.3, df=1, p=0.58).  
 
Qualitative assessment of intervention effect 
The answer to the open-ended question posed to IG patients at the end of the intervention period 
indicated that they perceived the procedures to be beneficial. IG patients felt that the most helpful 
part of the intervention involved using EM printouts for detecting problems, providing feedback, 
and defining proxy goals. Specifically, one patient appreciated that we cared about her 
medication management. She felt that the repeated discussions helped in reminding her to take 
the medications correctly.  
 
Discussion 
Our study is among the first to test an adherence-enhancing intervention in identified non-
adherent renal transplant recipients, showing that NAH can be modified in this patient 
population. The most important finding of our study is that mere inclusion resulted in a 
significant decline of NAH in both the IG and EUCG. The IG appeared to have also benefited 
further from the multidimensional intervention procedures we employed, although this effect 
failed to reach statistical significance. This study adds to the limited evidence on the effectiveness 
of adherence-enhancing interventions for medication regimens in other chronic patient 
populations. A methodological strength of our design was the use of EM, the most sensitive way 
to assess medication adherence [25-28]. The collection of sequences of binary EM data [30] 
allowed us to analyze in detail the time-component of medication non-adherence and to perform 
multiple modeling runs.  
Our observation of an inclusion effect merits further comment. When patients were invited to 
participate, they were informed that they had been identified as non-adherers in the previous EM 
study of post-transplantation medication compliance. This fact might have elevated awareness in 
patients, and thus could underlie the initial decrease in non-adherence observed in the two 
groups. If this hypothesized mechanism were in operation, our findings suggest that it would 
make sense to monitor patients for non-adherence and to provide feedback if it occurs. Indeed, it 
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should be imperative to include non-adherence as an important clinical parameter to be monitored 
in post-transplantation follow-up, given the major negative impact of non-adherence on outcome 
[1, 2, 32]. Measurement of non-adherence in daily clinical practice using EM, however, is not 
feasible. While EM is the gold standard for assessing non-adherence, we found previously that 
combining non-adherence information derived from various sources (i.e., self-report, collateral 
report, assay) is much more sensitive compared to single-measurement methods. More 
specifically, sensitivity of a composite adherence score shows 80% sensitivity in identifying non-
adherent RTx patients [33]. Patients’ self-report, despite its limitations of underreporting and 
recall bias [34], shows high specificity when questions are stated in a non-accusatory, 
information-intensive, and supportive manner [33, 35]. For instance, patients can be asked: “We 
know that taking medications after transplantation can be challenging. Some patients have 
difficulty in taking their prescribed drugs daily. How about you? Do you sometimes forget to take 
a dose? How often has this happened in the past week or month?” 
Our results suggest that the three-month intervention had an additional benefit on decreasing non-
adherence beyond the inclusion effect (Fig.2). However, the data lacked statistical power; thus, 
we were unable to make reliable statistical inferences on this point. Post hoc power analysis 
revealed that, in order to detect a significant difference in non-adherence between the study 
groups after 3 months, we would require a sample of 113 patients. This is with alpha set at 0.05 
and a power of 0.80 based on the χ2 effect size of 1.05. Our post-intervention questioning 
suggests, however, that the intervention effect may be reliable and that a larger study may be able 
to make a statistical statement about additional benefit derived from the kind of intervention 
procedures we used.  
The core strategy we used in the multidimensional, “high-dose” intervention was self-efficacy 
intervention. EM printouts were used as a tool for problem detection, feedback, and proxy goal 
setting. These allowed us to encourage mastery experiences and to initiate role modeling and 
verbal persuasion, known to be effective self-efficacy enhancing interventions. We employed 
additional individualized educational, behavioral, and social support interventions when 
appropriate. Since no patients in the intervention group was found to show depressive 
symptomatology (BDI>15) none of these patients were referred for further psychiatric evaluation 
or screening. Although our study design did not allow us to disentangle each discrete effect of 
these interventions, the interview at the end of the intervention period revealed that patients 
perceived the use of EM printouts and the associated self-efficacy interventions as most helpful 
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in increasing their medication adherence. This is in line with objective evidence, showing the 
effectiveness of self-efficacy interventions in improving adherence with smoking cessation [36] 
and maintaining exercise routines [37]. Improving self-efficacy is a behavioral intervention. Meta 
analyses comparing the effect sizes of different kinds of adherence-enhancing interventions with 
medication regimens confirm the superiority of behavioral interventions over other interventions 
(effect sizes: behavioral = 0.22; behavioral + educational = 0.35; affective = 0.20; educational = 
0.20) [12],[13]. 
Admittedly, the intervention we used was complex, very intense, and time consuming, which 
limits its use in routine clinical settings. Nevertheless, the basic principles and interventions 
applied in this study could be learned by members of the transplant team, allowing them to deal 
more effectively with non-adherent patients during routine hospital visits. A major obstacle to 
overcome is the prevalence of the acute-care model employed in most transplant follow-up care, 
meaning that no room is left for integrating adherence interventions into clinical practice. This is 
typically due to time constraints. An alternative might be to employ a chronic disease-
management model [16], [38, 39], in which not only medical but also psychosocial and 
behavioral dimensions of transplant management are optimally integrated into follow-up care. 
This would be more appropriate, given the increasing evidence that behavioral and psychosocial 
risk factors independently have a negative impact on clinical outcome in solid organ transplant 
populations. Chronic disease management also implies continuity of care, a strong emphasis on 
patients being an active partner in the clinical care, as well as the importance of adequate patient 
self-management [16], [38, 39].  
In generalizing our results to other patient populations, we should emphasize that the definition 
of non-adherence to immunosuppressive therapy we employed in the present study (see Table 1) 
is more stringent compared to the definition used with other medication regimens. For instance, 
with antihypertensive treatment, it is common to define medication non-adherence as adherence 
of less then 80%. Indeed, to guarantee favorable therapeutic outcomes in transplantation, nearly 
perfect adherence should be the goal, because minimal deviations from a dosing schedule are 
associated with negative outcome [2, 40]. The improvement in adherence levels in our renal 
transplant sample showed the feasibility of increasing adherence, even when baseline adherence 
levels were fairly high. This is especially important for medication regimens with limited 
forgiveness referring to narrow therapeutic windows such as regimens required for renal and 
heart transplant patients [40], [2] and HIV/AIDS patients on antiretroviral therapy [41], [42]. 
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Limitations of the study 
The main limitation of this study was the self-exclusion rate, which resulted in a small sample 
size. The power of the study, therefore, was not sufficient to make reliable statistical inferences 
about the efficacy of the main intervention. It surprised us that many of the patients declined to 
participate in the present study. We were especially surprised that many were unaware of being 
non-adherent in the previous study. This suggests that we should routinely use EM printouts 
before including patients in any research study in order to provide them with feedback on non-
adherence, which may in turn encourage them to participate in this kind of research.  
 
Conclusion 
Overcoming non-adherence in solid organ transplant populations could be a major pathway for 
improving clinical outcome. This study provides a first indication that behavioral intervention, 
especially self-efficacy intervention using EM methodology, is a feasible strategy for improving 
adherence in one class of identified immunosuppressive-regimen non-adherers. Our study has 
shown that this strategy can be incorporated into routine clinical care for RTx non-adherent 
patients. Additional large-scale studies are needed to test adherence-enhancing interventions in 
routine clinical care and to assess the impact of interventions on clinical outcome. 
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Abstract 
Objective: To test content validity and usability of the Organ Transplant Information System 
(OTISTM). 
Methods: This study used qualitative methods. The purposive sample consisted of 8 clinicians 
and 14 patients. Clinicians rated the content’s congruence with current medical practice. We used 
the clinicians’ evaluations to revise the OTISTM content; then each patient evaluated the revised 
OTISTM modules using the thinking-aloud method and via structured interviews. Descriptive 
statistics were applied for demographic and clinical data, and for the clinicians’ ratings. Content 
data usability and validity were analyzed using Content Analysis.  
Results: Clinicians identified deviations from current medical practice regarding content, 
language, and information structure of OTISTM. Seven rated OTISTM as non-relevant for 
implementation into clinical practice. Five rated the program’s content – with the stipulated 
adaptations – as important for patients. All patients encountered usability problems, mostly 
regarding the program’s interface. Emerging categories from the patients’ perspectives vis à vis 
content were knowledge acquisition, illness management, and partnership forming. 
Conclusion: Problems arose regarding OTIS’sTM initial content validity and usability, 
demonstrating the need to establish the presented material’s content validity and usability by 
involving clinicians and patients before its clinical implementation. 
Practice Implications: High quality computer-learning-software is needed to enhance patient 
self-management.  
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Introduction 
For chronic illness populations, “patient self-management” means continuous active involvement 
in their own care [1]. Gradually, patients develop expertise at managing their illness, thereby 
nurturing and influencing their daily decisions [1]. While the significance of such self-
management to health outcomes is widely acknowledged [1-3], however, patient self-
management is usually under-supported in clinical care, possibly due to time constraints in acute 
care settings. Therefore, effective interactive health communication applications [4-6] may offer 
valuable support.  
One such application, in use since 2001 at various transplantation clinics worldwide, is the Organ 
Transplant Information System (OTISTM) [7, 8], a computer assisted patient education package 
developed by Biocom Ltd, Zurich, Switzerland (see section 1.3.). Until this study, however, the 
program had never been systematically evaluated and validated. The purpose of this study was 
therefore to examine OTIS’s™ content and structure, particularly with regard to usability issues 
involving a group of potential end users.  
 
Transplant recipient self-management 
Kidney transplantation requires long-term treatment and follow-up care. Outcomes depend 
largely on effective recipient self-management, which requires support regarding knowledge, 
skills, and motivation. To guide both researchers and clinicians when aiming to enhance and 
support self-management using a comprehensive approach, we suggest a conceptual model 
derived from earlier research-based evidence in other chronic patient populations [9, 10]. In this 
paper, we focus on the “managing the medical regimen” segment, on which topic transplant 
research based evidence is available (see below). 
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Figure 1: Conceptual model of the (renal) transplant recipient’s self-management 
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As figure 1 shows, kidney transplant recipient self-management includes managing a medical 
regimen, emotions, and (new) life roles [9]. It may affect the patient’s family and/or 
community and should significantly influence interaction with healthcare professionals (outer 
circle). This may begin pre-transplantation (see arrow), with specific aspects assuming 
varying levels of importance at each stage. Finally, core skills [10] deemed reasonable for 
kidney recipients to have or acquire are specified in the small circles. 
All self-management practices of the (kidney) transplant population can be regarded as 
understudied except with regard to adherence to managing medical regimens, which has been 
found deficient, potentially leading to poor health outcomes. Non-adherence to 
immunosuppressive therapy occurs in an average of 28% of adult kidney transplant recipients 
(range 8-65%) accounting for 20% (range 2.5%-80%) of late acute rejections and 16% (range 
10%-64%) of all graft losses [11]. Suboptimal self-management is also prevalent in other 
aspects of the medical regimen, including inadequate sun protection [12-15], smoking, 
overweight [16, 17], sedentary lifestyle [3, 18], and failure to monitor relevant signs and 
symptoms [19, 20]. Among kidney transplant recipients, adherence self-management gaps 
suggest a need to integrate systematic patient self-management support into clinical transplant 
management applying state-of-the-art knowledge [3, 21]. While a small number of studies 
have evaluated attempts to enhance transplant medication adherence [22-24], related research 
suggests that improvements require frequent, time-intensive interventions combining 
educational, behavioral and social support [25-28]. However, in clinical settings, time 
constraints demand innovative uses of technology to help transplant recipients become active, 
knowledgeable partners in managing their therapy. 
 
The development of interactive health communication applications (IHCAs) 
The development of a technological intervention should include usability testing [29], to 
assure that the intervention allows users “to carry out their tasks safely, effectively, 
efficiently, and enjoyably” (p.56) [30]. Research on the usability of studied IHCAs programs 
during development showed that involving potential end users allowed the identification of 
otherwise unforeseeable usability issues [30-34]. Thus, IHCAs programs should be carefully 
evaluated with regard to both content and usability.  
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The Organ Transplant Information System™ 
Since 2000, in collaboration with transplant hospitals in the US, Germany and the UK (K. 
Youngstein [youngstein@biocom-ltd.com], e-mail, December, 30, 2007), Biocom Ltd. of 
Zurich, Switzerland, has been developing the Organ Transplant Information System 
(OTIS),™ a computer-based training and assessment program for transplant recipients [7, 8]. 
Intended to assist transplantation teams in enhancing patients’ self-management, OTIS™ 
consists of two applications: OTIS Education™ for patients and OTIS Editor™ for 
transplantation center staff. OTIS Education™ consists of six modules: 1) “pre-
transplantation”; 2) “your transplantation”; 3) “transplantation medicines”; 4) “your 
transplantation medicines”; 5) “rejection and infection”; and 6) “discharge from hospital”. 
The program contains texts and multimedia components such as simulations, graphics, and 
video recordings. OTIS Editor™ allows customization of medication-specific content. Since 
completion of an international OTIS™ prototype in 2003, adaptations have been made based 
on user feedback. However, while OTIS™ is available internationally, the program has not 
previously been evaluated formally regarding usability, content validity and efficacy 
concerning patient outcomes. 
This study’s aims were: 1) to evaluate OTIS’sTM content validity (i.e., the content’s congruity 
concerning both current medical practice and its intended use setting) from the perspectives of 
clinicians and patients; and 2) to test the application’s usability by target patients. 
 
Methods 
This study employed usability engineering [35] to test the degree to which OTIS™ allows 
users to navigate easily and perform tasks in a reasonable time, leading to the satisfactory 
achievement of intended aims [30]. Usability testing typically identifies problems users 
encounter when working with a tool. Data collection involved video observation and think-
aloud reporting [30, 35, 36]. 
 
Design 
We assessed clinicians’ evaluations using ratings, as well as qualitative content analysis of 
patients’ think-aloud recordings, observations and interviews (Figure 2). Data were collected 
from December 2005 to September 2006. The study protocol was approved by the “Beider 
Basel” cantonal ethics committee, and all participants provided written informed consent. 
Figure 2: Overview of the study’s design 
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Note: the arrows indicate the sequence of the 4 steps (i.e., 1 = first, 4 = last) undertaken 
during the study period. Clinicians reviewed the original OTISTM version (step 1), which we 
then revised regarding content (step 2), which resulted in an adapted OTISTM version (step 3), 
which was tested by patients (step 4).  
 
 
Sample and Setting 
We employed purposive sampling using the following patient/subject characteristics: age 
(older), computer experience (little or none), and time since kidney transplantation (various). 
We assumed that older patients with little or no computer experience would experience 
significantly more usability problems [37] than would a group of younger, computer-literate 
patients, since inexperienced computer users are more likely to struggle if the navigational 
structure of a program is not intuitive and self-explanatory [35]. Furthermore, involving 
patients at various times after transplantation demands that the content of the program 
contains material useful to patients with varying degrees of experience living with their 
transplants. The purposive sampling strategy ensured that patients representing an appropriate 
mix of characteristics reviewed each module pair. Patient inclusion criteria were: being either 
a kidney transplant candidate or kidney transplant recipient, receiving either treatment for end 
stage renal disease or post-transplant follow-up at the Basel University Hospital (USB), being 
adult, speaking German, being fully cognizant, literate and able to read a computer screen 
without difficulty, and having no functional impairments which would hinder navigation on a 
tablet personal computer (e.g., the inability to hold a stylus). We included eight specialized 
nephrological care clinicians. The study took place at the USB Transplant Immunology & 
Nephrology unit. 
 
original OTISTM 
Aim: to evaluate 
content validity 
Methods: 
Clinicians’ reviews 
Content revisions 
by researchers 
adapted OTISTM 
Aim: to evaluate 
content validity & 
usability 
Methods: Patients’ 
think-aloud responses, 
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1 2 
3 4 
Perspectives of end users: 
Clinicians 
Perspectives of end users: 
Patients 
Chapter 6: Computerized patient education in kidney transplantation: Testing the content 
validity and usability of the Organ Transplant Information System (OTISTM) 
123 
Variables and Measurements 
Clinicians’ recorded demographics were age, gender, and profession. Nephrology experience 
figures reflected years working in nephrology. Clinicians’ notes were written using a 
structured paper format to record their perspectives regarding the software’s content validity, 
and to identify content deviations from USB clinical practice guidelines (clinicians’ critical 
review). Two items (see Table 2, “Results”) assessed clinicians’ ratings of the software’s 
educational value to patients, and the relevance of the program regarding implementation into 
daily clinical practice. 
Patients’ recorded demographics were age, gender, and formal education. Medical variables 
were type of renal replacement therapy, and date of transplantation. Computer variables were 
prior computer experience. Usability data included tape-recorded think-aloud verbal 
responses and videotaped observations. Patients’ perspectives regarding content validity were 
obtained through transcripts of tape-recorded structured interviews asking how fully the 
program met their health and illness management needs (see Table 1 for specific questions). 
 
 
Table 1: Content validity of the program from the patients’ perspectives: Structured interview 
questions 
1. A. What did you like about the program? B. What did you not like? 
2. A. What was easy in using the program? B. What was difficult? 
3. Does the content of OTISTM meet your information and learning needs? 
A. If no, what would you recommend? 
B. What topics should be included in the program? 
C. What topics should be skipped? 
4. Would you use this program to learn about your illness, the transplantation and 
follow-up care, and your self-care? 
A. If yes, on which occasions? 
B. If no, why not? 
5. Would you recommend OTISTM to others? 
6. Should your relatives or significant others also use OTISTM to learn?  
A. If yes, what topics should be integrated into the program? 
B. If no, why not? 
7. What would you like to say that I haven’t asked about so far? 
 
 
Data collection procedures 
Clinicians’ evaluations 
To assess content validity data from the clinicians’ perspectives, the interviewer (a master’s 
degree level nurse with clinical expertise in renal transplantation) wrote comments while 
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reviewing the software modules. Clinicians provided feedback on two modules each, and each 
module was reviewed by either two or three clinicians. Next, the interviewer noted their two-
item interview responses concerning the value of the program and its relevance regarding 
clinical implementation. Content validity data from the clinicians’ critical reviews were used 
to adapt the content before testing it on patients (see Figure 2). 
 
Patients’ evaluations 
After explaining the study, the interviewer obtained written informed consent, then 
demographic and medical data from interested patients. She then instructed patients by 
demonstrating how to speak one’s thoughts while working with the software. Patients settled 
in front of the computer screen, where the interviewer showed them how to use the touch-
screen and stylus to navigate through the software, the touch-sensitive on-screen fields to 
access the software modules and sub modules, and the previous-page and next-page icons. A 
one-page summary of instructions was also provided, which specified the two modules the 
patient should work through (e.g., “Before Your Transplant”, and “Your Transplant”) as well 
as a personal password to log on to the software. The interviewer remained available while 
the patient worked through the software. The patients’ think-aloud responses were tape-
recorded and transcribed. The computer monitor and the patient were video-recorded, which 
helped to link the patients’ responses to the respective software screens, and captured the 
details of the patients’ navigation, along with system responses. The video-recorded 
observations of the patients captured the patients’ gestures, movements and facial 
expressions. These observations were reviewed and selected passages referring to usability 
problems transcribed. The structured interview following the completion of the two modules 
was also tape-recorded and transcribed verbatim. To save time, patients worked with only two 
modules each. After a maximum of 100 minutes, the interviewer terminated the think-aloud 
reporting, and continued with the structured interview, in which the patients’ impressions 
were elicited to assess the program’s content validity. The structured interview was tape-
recorded and transcribed verbatim.  
 
Data analysis 
Demographic and clinical data were summarized using frequencies, medians and ranges. 
Usability data analysis involved grouping response transcript excerpts according to issue type: 
interface related, content related or other [38]. The analysis of the video-taped observations 
focused on movements/gestures, and facial expressions with regard to agreement/comfort, and 
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disagreement/discomfort [32]. The interview transcripts were analyzed using Mayring’s 
content analysis techniques: text-bearing tracts were marked, then paraphrased; paraphrases 
were then generalized, summarized and grouped into inductively emerging categories [39]. 
The analysis was conducted by the first author, who met regularly with a group of senior 
expert researchers to discuss all findings. 
 
Results 
Clinicians’ perspective 
The Organ Transplant Information System program was critiqued by four nephrologists, three 
registered nurses and one renal dietician with a median of 10 years’ (min 2.5 – max 20) 
professional experience in nephrology. They invested a median total time of 95 minutes 
(range: 30-190) to review their allocated program segments. Six clinicians completed the 
review. The two who terminated their reviews cited the perceived poor quality of the OTISTM 
information, combined with the perceived lengthiness of the modules as their reasons for 
doing so. 
We summarized and grouped the clinicians’ critical evaluation notes into three main 
categories: content provided; language used; and information structure within OTISTM. The 
clinicians identified sections of OTISTM information that did not correspond to current 
medical practice. Table 2 depicts the categories, illustrated with examples of the negatively 
appraised material. Besides the negative criticism, positive comments were given to the 
following elements of the program: videos of patients narrating first-hand experiences and 
giving advice, and an interactive exercise on composing medication dosages. Five clinicians 
considered it important for patients to know the content of “an optimized” OTISTM program, 
but most (7 of 8) found OTISTM insufficiently relevant for clinical implementation (see Table 
2). 
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Table 2: Clinicians’ perspective of OTISTM 
Categories of the clinicians’ critical evaluations Clinicians’ ratings in view of the relevance and 
importance of OTISTM 
Category Critique Item Clinician ratings 
Content Many sections… 
a) did not correspond to current medical practice 
b) were medically incorrect 
c) contained lengthy text with low meaning 
Importance for patients to know 
the content of “an optimized” 
OTISTM program 
5 important 
1 neutral 
1 not important 
1 no answer 
Language The language was perceived to… 
a) be negatively burdened (with a potential to provoke anxiety) 
b) consist of long complicated sentences 
c) be burdened with complex medical terminology 
Structure A lack of a clear conceptual framework, leading to confusing information flow 
Relevance of implementing 
OTISTM (original version) into 
clinical practice 
1 relevant 
7 not relevant 
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Modifications to the original program 
Integrating the clinicians’ recommendations entailed reducing text, simplifying the remaining 
information, and adapting text to current medical practice. We reorganized information 
throughout for clarity and consistency. 
 
Patients’ perspectives 
The purposive 14-patient sample (9 male) had a median age of 60 years (range 41-75y) and 
included 4 kidney transplant candidates (3 on hemodialysis and 1 on CAPD) and 10 kidney 
transplant recipients (median time since kidney transplantation 37 months, range 5-426 
months). All had at least nine years’ formal education, and one had completed four years’ 
higher education. Eight had no computer experience, four used computers during leisure time 
only, and two used them for both work and leisure (median usage = 2 hours (range 0.5-20) per 
week). Nine patients required a median time of 89 minutes (range 31-97 minutes) to go 
through two modules of the program, and five did not complete the modules within the 
predefined maximum of 100 minutes. 
 
Usability 
We grouped participants’ responses and our observations of their difficulties during the 
cognitive tour of the program into three categories: interface related; content related; and 
other issues [38]. All participants encountered difficulties, mostly with the OTISTM interface. 
After 14 participants had completed the testing, we deemed the data’s redundancy level 
sufficient regarding the detection of usability problems, as the last three involved patients 
encountered no new issues. 
 
Interface related problems 
Interface related problems involved misinterpretation of navigation tools, inconsistency 
within the response cycle (see below), or non-comprehension of the structure and orientation 
of the modules and sub modules. For example, several participants were confused by buttons 
displaying people’s names (indicating videos of patients’ narratives), since buttons with 
functional labels (e.g., “start program”) had been used earlier in the program. The following 
quote illustrates this problem (quotes are in italic, observations in brackets): who is this Mr. 
Miller? Is this the writer of the program? [looks at interviewer] interviewer responds: He is 
one of the other patients who tell about their experiences [participant touches forward icon, 
backward icon, but not the button itself]. And how should that be functioning? 
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The goal-action-system feedback cycle (i.e., user ponders how to answer or move to next 
page – user clicks the appropriate button – system signals correctness/incorrectness or 
presents next screen) was also problematic. In one quiz, if the participant attempted to change 
an answer, the system would neither respond nor load the next question. The only functional 
option was to return to and re-answer the preceding question: Well, it (my answer) can only 
be wrong [participant touches button next to alternative answer: no response from system; 
participant looks astonished, touches this button again: no response from the system, 
participant sits back, breaths deeply, examines the screen]. Well, now, I can’t get any further. 
This requirement to go backward to proceed (and receive a response from the system) was 
inconsistent with the navigation in previous quizzes and beyond the scope of several 
participants to solve the situation and proceed. 
The structure and orientation of the modules and sub modules also consistently caused 
confusion: Now we are again through. Shall I continue with the menu button? [participant 
touches menu button, looks astonished] Well, we‘ve already had that, haven‘t we? [touches 
on introduction; (…) goes again into the same section that he has just completed; pauses] do 
they repeat everything? [long pause] Now, you have to help me. Irrespective of the specific 
module or sub module, participants consistently became disoriented. This became evident 
both through participants’ questions to the interviewers (often for information as to whether 
particular material had already been visited), and through observed behavior such as jumping 
from one sub-module to another or to unrelated material, or even terminating the program 
prematurely, having concluded (falsely) that they had completed it. 
 
Content related problems  
Content related problems applied both to meaningful learning aims and to medical 
terminology. They were present in an interactive exercise concerning viruses and diseases, a 
section on antiviral medications, and a section on possible complications following 
transplantation. Regarding antiviral medications and medical terms, problems occurred when 
participants recognized a particular virus (e.g., cytomegalovirus) they had contracted, but not 
the treatment indicated in the module (e.g., gancyclovir). This may have resulted from the 
program’s use of generic drug names, or from the patients having forgotten their treatment 
details. Further, some participants struggled with inadequately explained medical terms (e.g., 
acute tubular necrosis). 
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Other issues 
Other issues were linked to the software’s navigational structure or to the physical 
environment. Navigation related issues included shortages of links to related information 
pages or to alternative responses following quiz errors. Only one participant repeated several 
pages of information – which involved answering all questions again – in order to answer a 
question with which he was struggling. All other participants answered by trial and error, i.e., 
they touched the button next to the alternative answer and proceeded without repetition. 
Finally, environmental problems included various physical distractions (e.g., a fly in the 
room, noisy discussions in the corridor). 
 
Content validity 
Structured interviews (see table 1 for specific questions) were designed to learn whether the 
program met the participants’ information and learning needs regarding health and illness 
management. Emerging categories were gaining knowledge, managing the illness, and 
forming partnerships. 
 
Gaining knowledge 
Most participants believed that the program covered all relevant themes well and presented 
information unknown to them before. As one respondent commented, all important things are 
included: where I have to take precautions, what I need to do. Everything is well explained. 
This was the case for most participants, unless their stage within the illness trajectory did not 
correspond to the content of the modules in the program (e.g., if a patient who was seven 
years post-transplantation went through “Transplantation medicines”, which provides 
information regarding immunosuppressive drugs and other transplant related medications). In 
such cases the program had limited relevance, and was considered, at best, a useful review. 
However, participants spoke of the possibility to repeat modules at their own discretion as an 
important learning feature, which was supported if the content was perceived as easily 
readable, clearly explained and well-illustrated. 
New information was generally welcomed by participants, many of whom reported 
sometimes feeling they were informed about complications only if they were about to 
experience them and only if they asked explicitly for information. On the other hand, one 
participant explained that she would rather not know about every possible complication. She 
consequently read the pages of the program quickly and selectively.  
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Managing the illness 
Participants perceived that the program would help them to understand their illness, treatment, 
and follow-up care, and would increase their self-sufficiency regarding their conditions. Other 
patients’ narratives, presented through videos, contributed to this perception, as these 
narratives were affirmed to be “so true”. Viewing the videos, participants could identify, often 
very strongly, with the filmed patient, as each patient in the video had experienced waiting for 
and/or living with a transplant. Some participants realized that these patients had concerns 
similar to and sometimes more serious than their own. Thus, most perceived the videos as 
helpful. The program’s list of signs of infection and rejection was further perceived as helpful 
for knowing when to ask for assistance: According to this program, there can be noticeable 
signs (of rejection). If I felt such signs, I would go into the program to read again. And if they 
indeed had something to do with it, I would call my doctor. Concrete strategies and advice to 
monitor such signs, to prevent infections or skin cancer, and to support general health 
increased the sense of developing proficiency in managing the illness.  
 
Forming partnerships 
The participants agreed that the program facilitated communication with both health care 
professionals and significant others, including relatives and friends. Several believed the 
program would help them to address individual issues with their healthcare professionals, or 
to explain their illness and illness related events to their relatives and friends. Using the 
program would also develop their vocabulary, or fill time waiting or on dialysis with 
meaningful content.  
Some participants who applauded the program’s helpfulness for managing their illness 
concurrently emphasized that they did not wish to criticize their current courses of care. Some 
participants talked about doctors’ and nurses’ lack of time to inform and teach, and remarked 
critically that they had received information on some topics only following adverse outcomes. 
The participants considered their relationships with their healthcare professionals crucial. 
Where the program deviated from their doctors’ advice, then, they were confused. For 
example, one participant was puzzled by the program’s comment that immunosuppressive 
drugs could be taken with meals, as her doctor had advised her to take them between meals: I 
was informed and I asked again and I was clearly told yes, take Prograf® either one hour 
before or 1.5 to two hours after the meal. And you know, I have arranged it and this is not 
easy at all, I can say. Thus, conflict arose where the program deviated from, questioned or 
contradicted clinical counseling or the patient’s established routines. 
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Discussion and Conclusion 
Discussion 
This study evaluated the content and usability of OTISTM, a computer-based patient 
information and training program for transplant candidates and recipients. Although OTISTM 
had already been launched internationally in transplant clinics, this study was the first to 
evaluate it systematically from the perspectives of both clinicians and patients.  
 
Content validity from the clinicians’ perspectives 
The potential to use the OTISTM Editor to tailor content to a transplant center’s needs 
regarding medications is one of the software’s main strengths. However, the clinicians were 
disappointed by the large investment of staff time necessary before the package’s information 
could approach the standard provided by the clinic. This may explain why the majority of 
involved clinicians rated OTISTM as “irrelevant” regarding clinical practice.  
Several other explanations also warrant consideration. First, while other groups [5, 40-43] 
involved multidisciplinary teams as well as target patients early in the development of their 
programs, our clinicians expected a user-ready package designed in accord with current 
medical practice (i.e., based on current literature, and in cases of insufficient literature, expert 
opinion), which would allow, if necessary, customization of the content to match local 
practice. Where such expectations existed, however, they clearly went unfulfilled. Another 
possible explanation for the clinicians’ negative reactions is that, in many transplant clinics, a 
focus on acute care prevails, including a paternalistic relationship between clinicians and 
patients. Such a paradigm may explain – in part – why clinicians rated OTISTM as irrelevant. 
A shift towards a chronic illness management approach [2], whereby support of patient self-
management is considered a component of current medical practice [21], may make 
computer-assisted patient education a more valued addition to traditional clinical transplant 
care. It is, however, imperative that such programs offer information reflecting evidence 
based practice, which is often not the case [44-50].  
 
Usability 
Aided by a group of patients who are potential end users of the OTISTM software, this study 
further investigated the program’s usability. The data collection instrument combined 
observations with cognitive interviews, in which think-aloud responses allowed the 
researchers to map the mental activities of users while working with the software. This mix 
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very likely revealed more problems than would have been found by assessing patients’ 
reported perceptions alone.  
The study’s analyses highlighted a variety of usability issues, mostly related to the program’s 
user interface. These included misinterpretation of icons, loss of orientation within the 
modules, and inconsistency of system responses to user input. Some of these problems would 
be easily correctable (e.g., functional expressions of button labels). Others would be more 
difficult or unfeasible to solve in the OTISTM software. Disorientation within the modules, for 
example, may lead to skipped information, inadvertent repetition, anger, frustration, or 
becoming trapped and prematurely ending the learning session. None of these outcomes 
supports mastery experiences, an important factor both of learning [51] and of enhancing 
perceived self-efficacy [52]. Unfortunately, a suggested design revision to improve user 
orientation was deemed unworkable (P. Kaiser, personal communication, July 24, 2006).  
The significance of the encountered problems also warrants consideration. What happens 
when patients encounter the program in a clinical setting rather than a study? Based on the 
data gathered here, we strongly believe that several participants would be trapped in 
confusing situations. Such confusion would be actively counterproductive to the learning 
process [51, 53]. Furthermore, in a real learning situation, no clinician should be required to 
resolve usability issues: the goal of implementing the software is, after all, to leave clinicians 
free to help patients translate the presented information into productive behavior. 
 
Content validity from patients’ perspectives 
This study’s patients regarded the program as a valuable tool to complement current care at 
our transplant centre by facilitating learning, illness management, and partnership with 
healthcare professionals and significant others. These perceptions indicate some measure of 
success: becoming a knowledgeable partner and developing the ability to participate actively 
in one’s own care are key features of chronic disease management models [2]. Relevant 
information, motivation, and skill building are mutually beneficial factors influencing 
behavioral change [54]. These favorable perceptions could also result from under-
representation of highly-educated participants, who would potentially be more critical. An 
interviewer bias is also possible, since the interviewer was also known to the study 
participants as a healthcare provider. However, the favorable perceptions could also reflect 
the successful revision of OTISTM based on the clinicians’ evaluations.  
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Limitations of the study 
First, although the study’s sample can be considered adequate for usability testing [55, 56] (as 
evidenced by data redundancy regarding problems), it was certainly small. Second, to better 
understand the educational and informational needs of patients and their significant others 
(that can be translated into the content of such programs), further research is clearly 
warranted. For such a study, a larger sample of the target population would be advisable. 
Finally, we do not know how significant the usability problems were in terms of their effect 
on patients’ learning. However, we argue that such programs need to be carefully developed, 
leaving little room for problems when used. To facilitate learning, a user should be free to 
concentrate on and interact with the target content rather than with usability issues. 
 
Conclusion 
This study’s findings suggest that any IHCA’s content and usability both require testing and 
validation before such programs are launched for clinical use. Our formal testing revealed that 
the original OTISTM program was problematic. The revised OTISTM program was perceived 
as helpful to gain knowledge of the illness, treatment and necessary self-care to develop 
proficiency in managing the long-term condition of kidney transplantation. Regarding the 
achievement of this goal, studies of IHCAs’ long-term effects are necessary. 
 
Practice Implications 
Because patients take health information seriously, IHCAs’ content needs to be of high 
quality: a program offering wrong or useless information could result in counterproductive or 
even dangerous behavior.  
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Chapter 7 
Discussion, Conclusion, and Perspectives 
 
While recent decades have seen phenomenal advances in short-term graft survival, long-term 
perspectives have long been at an apparent impasse. Despite numerous improvements to 
immunosuppressive medication and other aspects of transplant management over the past 30 
years, 10-year graft survival rates have remained virtually static since the 1990’s [1]. The 
current challenge within transplantation is to improve those rates. Investing in transplant 
recipients’ self-management and medication adherence may clear the path for further 
progress.  
 
It is hoped that the current research program will play a meaningful part in this task. The 
following are the program’s contributions: 
 
First, using a chronic illness management care paradigm, we have defined and operationalized 
the elements of kidney transplant recipient self-management by summarizing evidence from 
the transplant literature. The resulting description provides a comprehensive framework 
including detailed transplant specific self-management activities and core skills for successful 
self-management. It is hoped that it will serve as a research and clinical guide for increasingly 
long-term management of transplant recipients.  
Besides numerous disease specific activities related to medical regimen management, patient 
self-management deals with emotions and new life roles, as well as with core patient skills 
(e.g., problem solving, decision making). Finally, it occurs in a broad context of interactions 
with family, community and the health care system. Still, while patient self-management 
obviously encompasses much more than adherence, adherence to the medical regimen has 
proven importance as a behavioral pathway to improve patient outcomes after transplantation. 
 
Second, in order to better understand medication adherence, we have provided a literature 
based overview of its correlates and interventions. This is complemented by a case study 
offering a practical approach to applying adherence enhancing strategies.  
 
Third, we have assessed the diagnostic accuracy of immunosuppressive drug assay, patient 
self-reports, clinicians’ collateral reports, and composite adherence scores, as tools to assess 
medication non-adherence. The results confirm previous evidence that current state-of-the-art 
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measures do not accurately assess medication non-adherence, particularly when used as single 
measures. Furthermore, our study provides evidence that diagnostic accuracy improves when 
measures are combined, as compared to single measures – a strategy suggested in a recent 
NEJM article [2], which we have now confirmed with empirical evidence from the transplant 
literature. 
 
Fourth, we conducted a pilot randomized controlled trial of a theory-based educational-
behavioral intervention and social support program designed to enhance medication 
adherence in non-adherent kidney transplant recipients. The study found an inclusion effect 
resulting in higher medication adherence in both intervention and usual care group, while the 
interventions also increased adherence. This pilot study adds to the very limited number of 
adherence enhancing intervention studies in transplantation using an appropriate 
methodological approach. 
 
As the fifth part of this research program, we evaluated e-health technology designed for 
transplant patients to learn about their illness, treatment and self-management activities. It is 
essential that technical interventions be tested, in view of usability, content validity and 
effectiveness, before their dissemination into clinical practice. Our examination focused on 
usability and content validity, both of which involve clinicians and patients who are potential 
end users of the program, and found major drawbacks regarding both content validity and 
usability. 
 
The following paragraphs discuss the main findings of the research program’s studies. 
 
Measuring medication adherence 
Using a convenience sample of 249 kidney transplant recipients, this cross sectional study 
used electronic monitoring as a reference standard to test the diagnostic accuracy of 
immunosuppressive assays, patient self-reports, clinicians’ collateral reports, and constructed 
composite adherence scores. Medication non-adherence’s prevalence across the measurement 
methods varied from 12.4% for self-reports to 38.9% for composite adherence scores. Of all 
the measures tested, the composite adherence score showed both the highest sensitivity 
(72.1%) and the highest likelihood ratio of a positive test (2.74), while collateral reports of at 
least three clinicians showed the highest specificity (93.1%). While no measures showed high 
sensitivity alongside high specificity, combining measures increased diagnostic accuracy, 
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indicating the relevance of combined measures for clinical and research purposes. This study 
thus confirms previous observations [3] that non-adherence rates are influenced by 
measurement methods, and also, as a review by Dew et al. [4] recently demonstrated, by 
operational non-adherence definitions and overall study quality. Furthermore, our study’s 
empirical evidence confirmed a previously suggested strategy [2] of combining several 
measures to produce superior diagnostic values. This is a suggestion that could doubtlessly be 
applied to numerous transplant studies, as only 17% currently use multiple methods [4], but 
none combined them. The majority of studies in the transplant literature surveyed used patient 
self-reports [5-28], while others immunosuppressive drug assays [8, 9, 18, 24, 26, 29-31], or, 
more recently, electronic monitoring [19, 23, 24, 32-39]. Small numbers preferred collateral 
reporting [24, 26], pharmacy refill records [29, 30, 40], or pill counts [26, 28, 41]. Further, 
until the current program, no study has combined adherence data from diverse sources to 
construct a composite adherence score. Adequate assessment tools are vital to medication 
non-adherence research, and thus to the development of interventions to improve related 
clinical outcomes.  
One often-problematic measurement method is the patient self report: patients tend to 
underreport non-adherence because of social desirability bias or simply because they forget 
[2]. Our study confirmed this method’s low sensitivity. In contrast, other work in 
transplantation [4, 24] and in other fields [42] have found patient self-reports a source of high 
non-adherence rates, possibly owing to more sensitive self-report methodologies (e.g., 
confidential in-depth interviews [24]) or different operational definitions of non-adherence 
[4]). The low expense and high feasibility of patient self reports in clinical settings certainly 
make them attractive as measures of medication adherence, especially when strategies are 
employed to maximize their reliability (e.g., building up a trusting atmosphere, conducting a 
confidential interview, detaching the occurrence of non-adherence from the concept of 
failure). Validation of specific self-reporting instruments will be the final hurdle to their 
widespread acceptance.  
Other non-adherence assessment instruments are subject to bias from sources other than the 
subjects themselves. Immunosuppressive blood assay levels are influenced by the drug’s half-
life, metabolic rates, drug-drug interactions, and white-coat adherence (i.e., greater adherence 
before a clinical visit) [43-45]; pill counts are invalidated when patients hoard or discard 
drugs [44, 46]; collateral reporting depends on the reporter’s familiarity with the patient [44, 
46]; and the fill frequency of prescriptions is problematic when patients use a number of non-
networked pharmacies [46-48]. Even the validity of electronic monitoring, although 
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justifiably used as a reference standard, can be compromised by incorrect use [49], by 
negatively impacting established adherence routines, or by improving normal adherence 
through an intervention effect [49]. No one perfect method has yet been devised. Based on 
our data, though, we recommend combining two or more measurement methods, including 
electronic monitoring. The combination of various methods to construct a final composite 
adherence score may be the most comprehensive technique to date, as each measurement 
method potentially assesses different aspects of non-adherence behavior. Taking or not taking 
medication is, after all, a behavior to be measured retrospectively–a task subject to a wide 
range of obstacles, few of which are easily seen. 
In summary, reliable measurements of medication non-adherence are essential to the 
discovery and correction of related problems in the transplant population. As no single perfect 
method is yet available, any information suggesting non-adherence, regardless of its source, 
should be taken seriously as a possible non-adherence indicator, and should be followed up 
with an in-depth adherence assessment. If non-adherence is confirmed, the clinician should 
then offer adherence-enhancing interventions.  
 
Medication adherence enhancing interventions 
In the literature on adult solid organ transplantation, research is rare on the efficacy of 
interventions to increase immunosuppressive medication non-adherence. Suggested 
interventions refer to educational approaches [29, 50, 51], internet-based interventions [52], 
financial support programs for medications [30, 53], electronic monitoring feedback [54], and 
self-medication administration program as part of discharge planning [53]. Few are 
randomized controlled trials and design issues (e.g., dimensional limitations, insufficient 
study periods, lack of theoretical support) limit their applicability. 
 
Our pilot intervention study used theory driven interventions and was built upon state-of-the 
art knowledge in view of adherence research. It is a pilot randomized controlled trial, testing 
the efficacy of an educational-behavioral intervention, including feedback on electronically 
monitored medication taking, in addition to enhanced social support to increase medication 
adherence in non-adherent renal transplant recipients. The results showed a remarkable 
decrease in non-adherence in both the intervention group and the enhanced standard care 
group over the first three months (IG, p=.04; EUCG, p=.06). The interventions appeared to 
benefit medication adherence levels more in the IG (which showed the greatest decrease in 
non-adherence). However, post-hoc power analysis (alpha set at 0.05, power set at 0.80, χ2 
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effect size of 1.05) revealed that 100 patients more than the sample used would have been 
required to detect a significant difference in non-adherence between the two groups.  
Despite this shortfall, the demonstrated effect that, for both study groups, inclusion in the 
intervention study decreased non-adherence remains significant. Combined with other 
findings, this implies that medication non-adherence should be regularly monitored and 
feedback provided based on a variety of non-adherence measures (e.g., patient self-reports, 
blood assay, clinicians’ collateral reports). 
It also warrants discussion that the inclusion effect was small. This finding is in line with a 
recent Cochrane review [55], which confirms previous evidence [56-59] that even the most 
effective interventions do not result in large improvements in adherence and treatment 
outcomes. However, any improvements in adherence levels are crucial, as evidence suggests 
that, for kidney transplant recipients, even small deviations from perfect adherence have a 
negative effect on clinical outcomes [40, 60]. 
While all of the above mentioned experimental intervention studies were classified as weak 
using the CONSORT quality appraisal instrument, our study was appraised as strong [61]. In 
fact, the majority of intervention studies in adult transplantation show major shortcomings 
related to methodology and/or intervention content. Content related shortcomings include the 
lack of a theoretical framework, unidimensionality (e.g., education) and unifactorial 
interventions (e.g., patient risk levels) not tailored to the individual situation. Methodological 
shortcomings include the use of non-randomized samples, the use of non-clinically-relevant 
operational definitions (e.g., of non-adherence), the use of invalid (e.g., single) measurement 
methods, the lack of a description of usual care, the lack of a control group, the lack of 
baseline adherence assessment, and the lack of an adequate sample size [61]. Subsequent 
trials will need to address all of these issues.  
Furthermore, besides resolving shortcomings related to intervention content and study 
methodology, future intervention studies may need to invest in the development and 
validation of innovative systems of assisting patients to follow long-term medication 
regimens [55]. The need for special care strategies to improve long-term patient outcomes 
motivates the current request to move towards a chronic care model for the management of 
long-term patient outcomes [62]. Such care models may integrate components such as 
technological interventions to support patients in managing their chronic illness in daily life 
[62-65]. Employing new technology to support transplant recipients’ self-management may 
be of particular help in current transplant clinics, as they are characterized by an acute care 
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paradigm, which allows insufficient resources (especially time) to invest in chronic illness 
management.  
 
Using technology systems to support transplant recipient self-management 
Information technology systems are becoming increasingly important in the health care 
system: e-health is believed to have great potential to benefit the management of chronically 
ill patient populations (Strategic health innovations in Oh, et al., [66]). In acutely driven 
health care systems such as transplantation, e-health related methodology to support patients 
in their self-management could be an instrument to optimize the use of clinicians’ time. The 
effectiveness of using technology to assist learning (e.g., using computer or web based 
educational software packages) has been widely demonstrated in educational science [67]. In 
health care, current evidence [68, 69] demonstrates that computer assisted or web based 
patient education is an effective tool to improve patient knowledge, social support, clinical 
outcomes (e.g., shortness of breath, pain, fatigue, and health distress), perceived self-efficacy 
(i.e., the confidence in one’s own ability to perform a certain task in a certain situation) and 
health behavior. 
Our first steps towards using e-health technology involved evaluating the content validity and 
usability of a computer-based patient information and training program proposed for use with 
transplant patients. The Organ Transplant Information System (OTIS)TM was evaluated from 
the perspectives of both clinicians and patients.  
The majority of the clinicians rated the original OTISTM version as “irrelevant” regarding 
clinical practice, a finding that reflected the lack of clinicians’ and patients’ involvement in 
the OTISTM development phase, as well as the clinicians’ perception that the program’s 
information was not relevant for patients, deviating fundamentally from their own clinical 
care, which includes providing patients with individualized (e.g., tailored, relevant, easy to 
understand) information in line with current medical care.  
Even programs currently in wide use may not often fulfil these criteria [70, 71]. For example, 
a systematic review of 79 empirical studies assessing the quality (i.e., accuracy, completeness, 
readability, design, disclosures, and references) of health information delivered via the 
worldwide web (www) found that 70% and 21% of the studies concluded that the quality was, 
respectively, poor or neutral; only 9% received a positive rating [70].  
Furthermore, our OTISTM study found inadequate readability of the presented material. 
Readability is a central quality issue of patient information/education [72-74], a problem new 
technologies appear to have inherited from traditional print media [71, 75]. This is evidenced 
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by studies reviewing the readability level of web-based patient education materials [71, 76]. 
Wallace et al. found that 75% of patient e-health information offered by the Academy of 
Family Physicians were pitched above an 8th grade level, which is considered the average 
reading level in the US [76]. A further review of 100 websites offering patient information on 
mamma, prostate and colon cancer found that the articles’ average reading grade level was 
12.9 – roughly the level necessary for university entrance. Further, the information was 
generally assessed as difficult according to the Flesh Reading Ease Index [71].  
These studies suggest that a major effort is still necessary to provide patients with easily 
understandable health information, whether written or oral. Additionally, illustrative visual 
materials should be central to patient education, as they support attention, recall, 
comprehension, intention and behaviour [77]. This principle applies to all patient educational 
resources, regardless of whether they are delivered as printed documents, CD/ROM/DVD’s, 
or over the worldwide web. 
While the majority of clinicians found OTISTM irrelevant for clinical practice, the majority of 
patients perceived the reworked program as a valuable tool to complement current care at our 
transplant centre. The discrepancy between the clinicians’ evaluation and patients’ 
perceptions regarding the content value of OTISTM could be the result of successfully 
reworking the content of the program based on the clinicians’ feedback. Patients perceived the 
program useful to facilitate learning, management of the illness, and partnership-building with 
healthcare professionals and significant others. Becoming a knowledgeable partner and 
developing the ability to participate actively in one’s own care are key features of a chronic 
disease management model [62]. The patients clearly saw OTISTM as a step in that direction. 
However, the study revealed major usability problems within the OTISTM software. Some of 
these were easily correctable while others would have been time intensive or impossible to 
resolve without a complete overhaul of the software. Such insoluble problems (e.g., user 
disorientation within the modules) led to skipped information, inadvertent repetition, anger, 
frustration and premature termination of learning sessions. These outcomes support neither 
self-management nor mastery experience – a factor vital both to learning and to enhancing 
perceived self-efficacy [78, 79].  
Other usability studies conducted during the development of educational material also involve 
groups of potential end users, who generally identify significant usability issues [80-83]. 
However, providing that these studies are conducted during the development phase of the 
program, these issues can be resolved with a minimum of expense before testing the 
program’s effect on patient outcomes. 
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To conclude, a computer or web based intervention tool to enhance transplant patient self-
management support should include only content with established validity, including both 
current disease specific, research based information and the training of disease and non-
disease specific skills. Furthermore, the development should be guided by proven software 
development methodology [81], including recently published research based usability 
guidelines [84], and involving clinicians and potential end users from the earliest possible 
stages. The development of the intervention is, after all, an intermediate aim: testing its effect 
on patient outcomes should be the focus of an intervention study. 
 
Strengths and limitations of the research program 
As investing in transplant recipients’ self-management and medication adherence is a 
potential pathway to improving long-term outcomes, one strength of this research program is 
that it represents a step towards developing a kidney transplant recipient self-management 
program. Additionally, exploring the field of e-health technology, it made progress toward 
resolving constraints on healthcare professionals’ ability to improve patient’s self-
management and medication adherence. Finally, the research program was comprehensive in 
applying various methods to answer the specific research questions. These included a cross 
sectional design study, a pilot randomized controlled trial, and also qualitative work.  
A limitation of the research program was its focus on medication management as a single 
example of kidney transplant recipient self-management of the medical regimen, and within 
this, the focus on measuring and improving medication adherence. However, medication 
adherence is an essential element of patient self-management, and is clearly linked to patient 
outcomes in transplantation. The studies on medication adherence addressed existing gaps in 
this field of research.  
A further limitation was that we only conducted a pilot randomized controlled trial to assess 
the efficacy of an adherence enhancing intervention, which limited the statistical inferences. 
Nevertheless, this study added to the scant information available in the transplant literature 
regarding the efficacy of medication adherence enhancing interventions. Furthermore, this 
pilot study was useful to design the “medication adherence enhancing strategies in 
transplantation and ophthalmology - MAESTRO-Tx” randomized controlled trial study which 
now runs in Leuven, Belgium [85]. 
Finally, the study evaluating the usability and content validity of the OTISTM educational 
software resulted in the decision, given its major drawbacks, that no further investment in this 
program was advisable. Therefore, it will be necessary to develop a new computer based or 
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web based patient self-management tool. Further work is also warranted to study kidney 
transplant recipient self-management with regard to managing emotions and life roles, and to 
address methodological challenges in adherence research in transplantation. 
 
Future research 
Future research should be performed to develop and test a patient self-management support 
intervention, and to address the current methodological challenges in transplantation 
regarding adherence research. 
To develop and test a patient self-management support intervention will require the following 
research steps. First, a systematic literature review is necessary to elaborate the most effective 
intervention in terms of improving patient outcomes. As no such interventions exist in the 
transplant literature, the literature of other chronic patient populations should be 
systematically reviewed with respect to components that are most effective in improving 
patient self-management. A special focus should thereby be given to intervention elements 
that belong to the development of knowledge or of patient skills, as patient self-management 
support systems that entail problem solving skills seem to be superior to interventions that 
train knowledge alone [86].  
Second, future studies need to further develop the conceptual model employed here to include 
descriptions of managing emotions and managing (new) life roles. Complemented by clinical 
expertise, a review of the transplant literature with regard to these skills should result in a 
comprehensive understanding of all components of kidney transplant recipient self-
management. Such an understanding is essential before adequate measures can be developed 
and validated, and before content information can be drafted. The development of 
intervention content should be based on research based knowledge (i.e., based on the renal 
transplant recipient self-management model) and include the perspectives of transplant 
patients and their families.  
More specifically, further studies should include representative samples of the target 
population to assess which of the transplant recipients’ and their families’ informational and 
educational needs can be translated into information content. Finally, the intervention 
program must be developed using proven software development methodology, including 
several rounds of usability testing [81, 84]. 
 
Further studies are also warranted regarding the current methodological challenges to 
transplantation adherence programs. To allow the simultaneous examination of adherence, 
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risk factors and outcomes, these should use longitudinal and prospective designs (e.g., 
transplant cohort studies).  
Second, future studies need a clinically meaningful definition of non-adherence, and the 
methods of assessing non-adherence should be derived from clear, explicit definitions of the 
domains to be measured. These, in turn, should be highly standardized and expressed as rates 
adjusted for follow-up duration (i.e., cases/100 persons/year) [4], while calculations should be 
based on data derived from multiple methods [2]. Additionally, in order to strength our grasp 
of the most reliable measurement methodologies, it will be necessary to design further studies 
that can compile and assess the value, appropriateness, and validity of a wide range of related 
strategies, both objective and subjective [42].  
Third, to ensure statistical power, statistical considerations (i.e., significance issues) imply 
that multicenter studies are needed to guarantee sufficient sample size and the possibility to 
perform analyses on subgroups whose outcomes might differ. Additionally, future studies 
should include random samples (rather than a convenience sample) to allow generalizability 
to the target population.  
Fourth, as only 3 of 7 intervention studies in the adult transplant literature included 
randomized controlled trials, the designs of future intervention studies clearly need to be 
improved. Additional design considerations in transplant intervention studies imply that 
baseline adherence should be assessed using a run-in period and a follow-up period to test a 
wash-out effect. The sustainability of the intervention should be included as a result, the 
collection of outcomes should be blinded, and a factorial design should be applied to 
disentangle the effects of the various intervention components. Regarding the content of 
adherence enhancing interventions, future studies should use literature based and theory 
driven interventions, and interventions based on available meta-analyses of chronically ill 
patient populations, specifying the intervention dose and duration.  
Fifth, to assess the clinical and economic relevance of non-adherence to immunosuppressive 
drugs, future intervention studies in transplantation should also include clinical and economic 
outcomes as primary results.  
Finally, data analyses should include time dependent analyses and should imply survival 
analysis or mixed effects models for repeated measurements, taking any missing data into 
account. Also, analyses of intention to treat should be performed rigorously, and effect sizes 
should be reported for all outcomes, as they are the basis for meta-analysis as well as for the 
evaluation of clinical significance. Such efforts clearly have the potential to deal with the 
methodological challenges currently facing transplant medication adherence research [87-89]. 
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Conclusion 
We conclude that our research program was innovative, offering, for the first time, a 
definition of kidney transplant recipient self-management. It adds to the existing knowledge 
regarding the diagnostic values of state-of-the-art measures of medication non-adherence, as 
well as of interventions to enhance medication non-adherence. Doing so involved entering the 
promising field of e-health technology as it applies to kidney transplant patient care and 
support. This research program has also enabled us to outline specific issues and additional 
topics of interest for further research to understand and support patient self-management in 
the kidney transplantation population.  
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